



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07C 275/30, C07B 57/00, B01D 15/08, C07C 271/38, C07D 209/48, C07C 251/20, 233/65		A2	(11) International Publication Number: WO 96/40627 (43) International Publication Date: 19 December 1996 (19.12.96)
(21) International Application Number: PCT/US96/07121		(81) Designated States: AU, CA, JP, KR.	
(22) International Filing Date: 17 May 1996 (17.05.96)		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(30) Priority Data: 08/482,497 7 June 1995 (07.06.95) US 08/480,203 7 June 1995 (07.06.95) US 08/480,204 7 June 1995 (07.06.95) US 08/482,430 7 June 1995 (07.06.95) US 08/482,305 7 June 1995 (07.06.95) US 08/480,622 7 June 1995 (07.06.95) US			
(71) Applicant: GEN-PROBE INCORPORATED [US/US]; 9880 Campus Point Drive, San Diego, CA 92121-1589 (US).			
(72) Inventors: SRIDHAR, C., Nagaraja; 1911 East Larch Street, Simi Valley, CA 93065 (US). DATTAGUPTA, Nanibushan; 4221 Kerwood Court, San Diego, CA 92130 (US). PATEL, Jasmin, R.; 10030-52 Scripps Vista Way, San Diego, CA 92131 (US). DAS, Aditya, Ranjan; Apartment 241, 7867 Avenida Navidad, San Diego, CA 92122 (US).			
(74) Agents: SCHNEIDER, Carol, A. et al.; Lyon & Lyon, First Interstate World Center, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).			

(54) Title: THIOLATIONIC LIPIDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF

(57) Abstract

Lipid molecules bearing a cationic charge are described. These cationic lipids are useful in the delivery of biomolecules, such as oligonucleotides, nucleic acids, peptides, diagnostic imaging agents, proteins and drug molecules. In the form of liposomes, they can effectively be used for the intracellular delivery of biomolecules for therapeutic or diagnostic purposes.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

DESCRIPTIONThiocationic Lipids, Pharmaceutical Compositions
And Methods Of Use ThereofField of the Invention

The present invention relates to synthetic cationic lipophilic compounds. In particular, it relates to thiocationic lipids that have a positively charged sulfonium ion, and the use of such thiocationic lipids as constituents of biomolecule conjugates and complexes, and pharmaceutical compositions thereof.

Background of the Invention

Biomolecule-containing formulations, such as *in vivo* therapeutic agents, must be capable of exerting their effects on biological systems without causing toxicity and without first being degraded by normal biological processes. This sometimes requires the use of complex delivery systems and chemical modifications to make otherwise toxic and unstable compounds more efficacious. In particular, pharmaceutical agents which are highly charged, insoluble and/or high molecular weight sometimes have limited pharmacological usefulness unless they are coupled to a carrier or incorporated into a delivery vehicle.

The problems associated with successful administration of pharmaceutical formulations are compounded by the fact that certain types of pharmaceutical agents cannot exhibit their biological effects unless they are taken up by cells. For example, the use of oligonucleotides as modulators of gene function depends on their ability to interact with cellular components at the intracellular, and sometimes intranuclear, level. However, oligonucleotides, as well as other polyanionic substances, exhibit poor cellular uptake when delivered in aqueous solution.

Many different approaches have been suggested for enhancing intracellular uptake of oligonucleotides. Some involve biological approaches, such as the use of viral vectors (Cepko, et al., *Cell* 37: 1053-1062 (1984)), or the covalent attachment of cell receptor ligands (Myers, et al., European Patent No. 273,085 (1988); Wu et al., *J. Biol. Chem.*, 263: 14621-14624 (1988); and Vestweber, et al., *Nature* 338: 170-172 (1989)). Others involve physical approaches, such as the direct microinjection of DNA into cells (Capecchi, et al., *Cell* 22: 479-488 (1980)) or cellular electroporation (Potter et al., *Proc. Nat. Acad. Sci.* 81: 7161-7165 (1984)). Yet others involve predominately chemical approaches, such as the attachment of lipophilic moieties (Shea, et al., *Nucleic Acid Research* 18(13): 3777-3787 (1990); MacKellar, et al., *Nucleic Acid Research* 20(13): 3411-3417 (1992)) or polypeptides (Stevenson, et al., *J. Gen. Virol.*, 70: 2673-2682 (1989)).

Delivery vehicles such as liposomes have also been described for use in the intracellular delivery of oligonucleotides. (Felgner, et al., U.S. Patent No. 5,264,618 (1993); Eppstein, et al., U.S. Patent No. 4,897,355 (1990); and Wang, et al., *Proc. Nat. Acad. Sci.* 84: 7851-7855 (1987)). An advantage of using liposome formulations is the ability of these substances to mimic naturally occurring cellular membrane substituents. This encourages fusion with cellular and endosomal membranes, which results in delivery of the liposome contents into the cytoplasm. Without such membrane fusion, extracellular substances are taken up by endocytosis and may be degraded within phagosomes before being released into the cytoplasm.

Liposomes which are most useful for the intracellular delivery of biomolecules are often complex formulations containing mixtures of different lipophilic substituents. These complex mixtures allow for optimi-

zation of the physical properties of the liposomes, such as pH sensitivity, temperature sensitivity and size. One recent advance is in the recognition that certain pH sensitive amphiphilic compounds, such as dioleoyl-
5 phosphatidyl-ethanolamine ("DOPE"), can be used to formulate liposomes which destabilize at acidic pH. This promotes fusion of the liposome with endosomal membranes when exposed to the degradative acidic pH and enzymatic contents of the endosome, which results in
10 release of the contents of the lysosome into the cytoplasm. (See Ropert, et al., Biochem. Biophys. Res. Comm. 183(2): 879-895 (1992); and Juliano, et al., Antisense Research and Development 2: 165-176 (1992)). The inclusion of sterols in liposomes is also
15 commonplace. In general, the presence of sterols in liposome formulations results in enhanced stability, both *in vitro* and *in vivo*. Liposome formulations for the delivery of biomolecules which contain organic acid derivatives of sterols, such as cholesterol or vitamin
20 D₃, have been reported to be easier to formulate than their non-derivatized water-insoluble equivalents (Janoff, et al. U.S. Pat. No.s 4,721,612 and 4,891,208). However, in complex liposomal formulations containing certain polar lipids, the inclusion of such water
25 soluble acid sterol derivatives may destabilize liposomes and thus diminish efficacy.

Cationic lipids (i.e. derivatives of glycerolipids with a positively charged ammonium or sulfonium ion-containing headgroup) are particularly useful in
30 liposomal formulations for the intracellular delivery of negatively charged biomolecules, such as oligonucleotides. Their usefulness may be derived from the ability of their positively charged headgroups to interact with negatively charged cell surfaces. The
35 cationic lipid N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride ("DOTMA") is described by Felgner et al. (Proc. Nat. Acad. Sci. 84: 7413-7417 (1987); see also U.S. Patent No. 4,897,355). Therein, a

cationic lipid having an ammonium group is used in a liposome formulation to facilitate transfection of cells by polynucleotides. In these formulations, DOTMA has been shown to spontaneously interact with DNA to form 5 ionic lipid-DNA complexes that are capable of fusing to negatively charged lipids on cell surfaces, ultimately leading to the uptake of DNA by the cell.

Several other ammonium ion-containing cationic lipid formulations have also been reported for such 10 applications. These formulations include a DOTMA analog, 1,2-bis(oleoyloxy)-3-trimethylammonio)propane ("DOTAP") (Stamatatos et al., *Biochemistry*, 27: 3917-3925 (1988)); a lipophilic derivative of spermine (Behr et al., *Proc. Nat. Acad. Sci.*, 86: 6982-6986 (1989)); 15 and cetyltrimethylammonium bromide (Pinnaduwage et al., *Biochim. Biophys. Acta*, 985: 33-37 (1989)) (See also Leventis et al., *Biochim. Biophys. Acta*, 1023: 124 -132 (1990); Zhou et al., *Biochim. Biophys. Acta*, 1065: 8-14 (1991); Farhood et al., *Biochim. Biophys. Acta*, 1111: 20 239-246 (1992); and Gao, et al., *Biochim. Biophys. Res. Commun.*, 179: 280-285 (1991)). Some commercially available cationic lipids include DOTMA (Gibco BRL, Bethesda, Maryland), DOTAP (Boehringer Mannheim, Germany), and 1,2-diacyl-3-trimethylammonium propane 25 ("TAP") (Avanti Polar Lipids, Birmingham, Alabama). However, many of these ammonium ion-containing lipids have been reported to be cytotoxic.

Sulfonium ions have entirely different physical properties than ammonium ions. In fact, ammonium ion-containing compounds are classified as hard bases, because the nitrogen atom possesses high electronegativity, is hard to polarize and oxidize, and the valence electrons are held tightly by the nucleus. This characteristic may account for some of the toxicity 30 35 associated with ammonium ion-containing lipid formulations. In contrast, sulfonium ion-containing compounds are classified as soft bases, because the sulfur atom possesses low electronegativity, is easy to polarize and

oxidize, and the valence electrons are held more loosely by the nucleus. This decreased charge density exhibited by sulfonium ion-containing (i.e. "thiocationic") lipids may effectuate an enhanced interaction with negatively charged cellular membranes, as well as a decreased toxicity.

It has also been suggested that one important feature which is associated with the usefulness of lipids in enhancing transfection is the size of their headgroups. Formulations containing cationic lipids with "relatively small polar headgroups" have been predicted to be most useful (Felgner, et al., *J. Biol. Chem.* 269(4): 2550-2561 (1994)). In addition, Morris-Natschke, et al., (*J. Med. Chem.* 36: 2018-2025 (1993)) describe the use of phosphocholine ether lipids, including a sulfonium derivative, as anti-neoplastic agents, and report that the presence of large headgroup substituents decreased efficacy.

Because of the physiochemical properties of the sulfonium ion, a thiocationic lipid with a larger headgroup may be preferred. Particularly, when the lipid headgroup consists of a sulfur atom surrounded by adjoining saturated carbons, the sulfonium ion will exhibit a diffusion of charge to the neighboring carbons that may facilitate interaction of the lipid with cellular membranes, as well as decreasing toxicity.

Although the previously described ammonium and sulfonium ion-containing lipids have been shown to be useful in many therapeutic applications, their incorporation into and use in the form of complex liposomal formulations has yet to be optimized. In particular, the enhanced efficacy which is achieved by incorporating Vitamin D into cationic lipid-containing formulations has not been explored.

It is therefore an object of the present invention to provide thiocationic lipids which are less toxic in pharmaceutical formulations than their ammonium ion-containing counterparts.


It is also an object of the present invention to provide thiocationic lipid-containing pharmaceutical formulations which enhance the intracellular delivery of biomolecules to a greater extent than previously 5 described lipophilic compounds.

It is a further object of the present invention to provide cationic lipid-containing liposome formulations which demonstrate superior efficacy.

Summary of the Invention

10 The present invention relates to novel sulfonium ion-containing cationic lipids ("thiocationic lipids") and their use in pharmaceutical formulations for the intracellular delivery of biomolecules. These novel compounds are glycerolipids with headgroups which 15 contain a sulfonium ion surrounded by at least three neighboring carbon atoms that serve to beneficially diffuse the positive charge of the sulfonium ion.

In particular, the present invention relates to thiocationic lipids of the general formula:



and optical isomers and/or salts thereof wherein:

A^1 and A^2 are the same or different and are $-\text{O}-\text{CO}-$, $-\text{O}-$, $-\text{S}-\text{CO}-$ or $-\text{S}-$;

30 A^3 is $-\text{O}^-$, $-\text{O}-\text{CO}-$, $-\text{CO}-\text{O}-$, $-\text{S}-$, $-\text{S}-\text{CO}-$, $-\text{CO}-\text{S}-$, $-\text{O}-\text{CS}-$, $-\text{CS}-\text{O}-$, $-\text{CO}-\text{NH}-$, $-\text{NH}-\text{CO}-$, $-\text{CS}-\text{NH}-$, $-\text{NH}-\text{CS}-$, $-\text{NH}-\text{CO}-\text{O}-$, $-\text{NH}-\text{CO}-\text{NH}-$, $-\text{O}-\text{CO}-\text{NH}-$, or is absent;


R^1 and R^2 are the same or different and are H , or C_1 to C_{23} saturated or partially unsaturated alkyl or 35 aralkyl, with the proviso that at least one of R^1 and R^2 is not H ;

R³ is a C₁ to C₁₂ alkyl, aralkyl, alkaryl, heterocyclyl or heteroaryl; or

R³ is an amino acid, a dipeptide, a tripeptide, a tetrapeptide or a pentapeptide; or

5 R³ is -[(CH₂)_p-NR⁴]_q-R⁴,

- (CH₂)_p-NR⁴₃⁺,



wherein p is 1 to 5, q is 0 to 4, and R⁴ is H or a C₁ to C₄ alkyl; and

m, n and o are 0 to 8 with the provisos that m ≥ 1 and m + n + o ≥ 3.

20 These cationic lipids may be used in pharmaceutical formulations in the form of complexes with a biomolecule either alone or in combination with other lipid substituents. Alternatively, they may be covalently conjugated to biomolecules and used as such in

25 pharmaceutical formulations.

Pharmaceutical formulations according to the present invention consist of these complexes or conjugates and a pharmacologically acceptable carrier. Examples of pharmacologically acceptable carriers

30 include aqueous solutions and complex delivery systems. Preferably, the pharmacologically acceptable carrier is a liposome.

An important aspect of the present invention is the discovery that certain cationic lipid-containing

35 liposome formulations for use in the intracellular delivery of biomolecules exhibit enhanced efficacy. Such liposomes generally consist of an ammonium or

sulfonium ion-containing lipid, Vitamin D, a pH sensitive amphiphile, and a biomolecule.

Other features and advantages of the invention are apparent from the following detailed description and the 5 claims.

Brief Description of the Drawings

Figure 1 illustrates the viral inhibition of a liposome formulation containing DOMCATOP and an anti-HIV antisense oligonucleotide.

10 Figure 2 illustrates the viral inhibition of a liposome formulation containing DODMECAP and an anti-HIV antisense oligonucleotide.

15 Figure 3 illustrates the viral inhibition of a liposome formulation containing either cholesterol or Vitamin D3, and an anti-HIV antisense oligonucleotide.

20 Figure 4 illustrates the effects of liposome formulations containing either DODMEHAP or DOMHYTOP and an anti-HIV antisense oligonucleotide on cellular metabolic activity.

25 Detailed Description of the Preferred Embodiment

The present invention provides a new class of synthetic thiocationic lipids that possess a sulfonium ion in the lipid head group. These thiocationic lipids are useful for enhancing the intracellular delivery of 25 biomolecules by serving as constituents of covalent conjugates and/or components of pharmaceutical formulations. In order to more clearly describe the subject matter of the present invention, certain terms used herein shall be defined as follows unless otherwise 30 indicated:

Alkaryl: "Alkaryl" means an aryl group bearing at least one alkyl substituent, for example tolyl or t-butylphenyl.

35 Alkenyl: "Alkenyl" means an alkyl group or moiety having at least two carbons joined to each other by a double bond.

Alkyl: "Alkyl" means straight chain or branched chain hydrocarbon group or moiety. When used alone, the term alkyl refers to a fully saturated hydrocarbon group.

5 Alkynyl: "Alkynyl" means an alkyl group or moiety having at least two carbons joined by a triple bond.

10 Amphiphilic: "Amphiphilic", when used to refer to an organic compound, means that the compound consists of both a hydrophobic (non-polar) moiety and a hydrophilic (polar) moiety. Examples of amphiphilic compounds include sodium oleate; phosphatidylcholine and derivatives thereof, such as dioleylphosphatidylcholine ("DOPC"); and dioleylphosphatidylethanolamine ("DOPE").

15 Antisense Oligonucleotide: "Antisense oligonucleotide" means an oligonucleotide which is complementary to a target "sense" nucleic acid, and functions at least partially by sequence-specific mechanisms to regulate the functioning of the target nucleic acid.

20 Aralkyl: "Aralkyl" means an alkyl group to which is attached at least one aryl ring moiety, for example benzyl, phenethyl or benzhydryl.

25 Aryl: "Aryl" means an aromatic hydrocarbon group or moiety, such as phenyl or naphthyl.

30 Biomolecule: "Biomolecule" means an organic compound which has a desirable biological activity or function, i.e. a "biological effect", *in vivo*. For example, biomolecules consisting of therapeutic agents may alter cellular functions, such as gene functions.

35 Alternatively, biomolecules consisting of diagnostic agents, such as magnetic resonance imaging ("MRI") or computerized tomography ("CT") agents, have the biological function of enhancing the diagnostic images of tissues and/or organs.

40 Complementary: "Complementary", when used to refer to a nucleic acid, means a nucleic acid of one polarity containing a sequence of nucleotides whose bases pair via Watson-Crick hydrogen bonds with the nucleotide

bases of another nucleic acid of opposite polarity, i.e. adenine ("A") pairs with thymine ("T") or uracil ("U"), and guanine ("G") pairs with cytosine ("C"). For example, a nucleic acid having the sequence GCAU in the 5' to 3' direction is "complementary" to a nucleic acid having the sequence CGTA in the 3' to 5' direction. Use of the term complementary herein is intended to include those nucleic acids which are substantially complementary. Complementary nucleic acids can also be referred to as one being the plus ("(+)") or "sense" strand and the other being the minus ("(-)") or "antisense" strand.

Complex: "Complex" means a non-covalent physical, usually ionic, association between two or more compounds. Examples of complexes include, for example, a negatively charged oligonucleotide which is ionically associated with a cationic lipid.

DODMECAP: "DODMECAP" means 1,2-dihexadecyloxy-3-(N-(5-carboxypentyl)-N,N-dimethylammonio)propane, and isomers and/or salts thereof.

DODMEHAP: "DODMEHAP" means 1,2-dihexadecyloxy-3-(N-(6-hydroxyhexyl)-N,N-dimethylammonio)propane, and isomers and/or salts thereof.

DOMCATOP: "DOMCATOP" means S-((2,3-dihexadecyloxy)propyl)-S-(5-carboxypentyl)methylsulfonium, and isomers and/or salts thereof.

DOMHYTOP: "DOMHYTOP" means S-((2,3-dihexadecyloxy)propyl)-S-(6-hydroxyhexyl)methylsulfonium, and isomers and/or salts thereof.

DOPC: "DOPC" means dioleylphosphatidylcholine.

DOPE: "DOPE" means

dioleylphosphatidylethanolamine.

Glycerolipid: "Glycerolipid" means a lipophilic molecule bearing a glycerol backbone, at least one hydrophobic tail, and which may also contain a hydrophylic polar headgroup.

Headgroup: "Headgroup" means that portion of a glycerolipid which is attached to the glycerol backbone at one of the terminal carbons. Headgroups can be neutral or polar.

5 Heteroaryl: "Heteroaryl" means an aromatic group bearing at least one heteroatom as part of the aromatic ring structure, for example pyrrolo or pyridyl.

10 Heterocyclyl: A cyclic group bearing at least one heteroatom as part of the ring structure, for example piperidinyl, pyrrolidinyl or morpholino.

15 Hybridize: "Hybridize" means the formation of a duplex between complementary nucleic acids via base pair interactions.

20 Liposome: "Liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.

25 Modified: "Modified", when used to refer to a nucleic acid, means a nucleic acid in which any of the natural structures have been altered. These include modifications to the phosphodiester linkages, the sugars (ribose in the case of RNA or deoxyribose in the case of DNA) and/or the purine or pyrimidine bases. Modified phosphodiester linkages include phosphorothioates, phosphotriesters, methylphosphonates and phosphorodithioates.

30 Nucleic Acid Sequence: "Nucleic acid sequence", or "sequence", means both a nucleic acid having a particular sequence of nucleotides, and also the sequence or order of nucleotides present in a particular nucleic acid. Which of these two meanings applies will be apparent from the context in which this term is used.

35 OBEHYTOP: "OBEHYTOP" means S-((2-benzyloxy-3-octadecyloxy)propyl)-S-(6-hydroxyhexyl)methylsulfonium, and isomers and/or salts thereof.

40 OBECATOP: "OBECATOP" means S-((2-benzyloxy-3-octadecyloxy)propyl)-S-(5-carboxypentyl)methylsulfonium.

OA: "OA" means oleic acid.

Oligonucleotide: "Oligonucleotide" means a short segment of a nucleic acid.

Pharmacologically compatible carrier:

"Pharmacologically compatible carrier" means a 5 formulation to which a biomolecule can be added to facilitate its administration to a patient without exhibiting any unacceptable levels of toxicity or pharmacologically adverse effects.

Phosphorothioate oligonucleotide: "Phosphorothioate 10 oligonucleotide" means an oligonucleotide having all phosphorothioate linkages in place of naturally occurring phosphodiester linkages.

Polyanion: "Polyanion" means a molecule bearing more than one negative charge.

15 Sequence: "Sequence" means the pattern or order of the nucleotide bases (A, G, C; T or U) in a nucleic acid.

Therapeutically effective amount: "Therapeutically effective amount" means an amount which is sufficient to 20 demonstrate a biological effect which is sufficient to produce a desired therapeutic benefit.

The usefulness of the thiocationic lipids of the present invention is enhanced by the presence of a well-distributed positive charge in the lipid headgroup, 25 which allows for efficient interaction with negatively charged cellular membranes. The preferred use of these thiocationic lipids is in the intracellular delivery of negatively charged biomolecules. The thiocationic lipids also function to balance the negative charges on 30 such biomolecules which makes the resultant formulations more charge neutral. A particularly preferred use is in the intracellular delivery of oligonucleotides, for example phosphorothioate oligonucleotides. They may also be useful in the intracellular delivery of certain 35 diagnostic imaging agents, such as iodine-containing CT agents.


The thiocationic lipids of the present invention are designed to mimic naturally occurring cellular

membrane constituents. This allows the thiocationic lipid, and any associated biomolecule, to fuse with the cellular membrane thus facilitating intracellular delivery. Without being able to efficiently fuse with 5 cellular membranes (which is sometimes referred to as a substance's "fusogenic" property), foreign objects are phagocytized and quickly degraded by lysosomal enzymes.

I. Thiocationic Glycerolipid Structure

10 The novel thiocationic lipids of the present invention can be represented by the general formula of Structure I:

15




Structure I

20 and optical isomers and/or salts thereof.

The thiocationic lipids given by Structure I can be described as having three separate moieties; a backbone, one or more tailgroups and a headgroup. As given above, the backbone is composed of the three-carbon glycerol 25 moiety; the tailgroups are given by R^1 and R^2 , and are attached to the backbone via A^1 and A^2 ; and the headgroup is given by;

30



The thiocationic glycerolipids of the present invention contain a positively charged sulfonium ion, S^+ . The sulfonium ion has the advantage of providing a lower charge density as compared to a positively charged 35 ammonium ion. In combination with the surrounding carbons in the headgroup, the positive charge is

diffused, thus permitting enhanced interactions with negatively charged cell surfaces, as well as improved efficacy. Thus, m , n and o are each from 0 to 8, with the proviso that $m \geq 1$, and $m + n + o \geq 3$.

5 A^1 and A^2 provide the linkage between the glycerol backbone and the lipophilic tails. A^1 and A^2 can be the same or different and are -O-CO-, -O-, -S-CO- or -S-. Particularly preferred embodiments are compositions wherein both A^1 and A^2 are -O-, and R^1 and R^2 are long
10 chain (C16 to C18) alkyl moieties linked to A^1 and A^2 via a -CH₂- moiety. These long chain alkyl ether lipids are metabolically more stable than ester based lipids, and have been found to be superior in transporting nucleic acids into cells. A particularly preferred compound of
15 this type is DOMHYTOP, or its carboxyacid derivative, DOMCATOP. See Example I Parts A and B, respectively.

Another aspect of the present invention is the ability to vary the hydrocarbon chain length of the R^2 moiety in order to selectively manipulate the formation
20 of preferred liposome structures. For example, when A^2 is -O- and R^2 is H, the glycerolipid (i.e. "lysolipid") thus formed will have a single tailgroup. Use of lysolipids in combination with lipids having longer chain R^2 moieties may favor the formation of liposomes
25 having one or more bilayers. Use of lysolipids alone favors the formation of micelles. Such mixed lipid formulations can be optimized for size and cellular uptake by varying the ratio of components accordingly.

Another preferred class of thiocationic lipids
30 according to the present invention are compounds wherein A^2 is -O-, and R^2 is the aralkyl CH₂C₆H₅. These benzyl derivatives have increased hydrophobicity due to the presence of the aromatic moiety, and as such may exhibit preferred formulation characteristics. A particularly
35 preferred compound of this variety is OBEHYTOP, or the equivalent carboxyacid derivative, OBECATOP. See Example I Parts C and D, respectively.

It is also possible to incorporate R¹ and R² moieties having varying degrees of unsaturation in order to optimize the fusogenic properties and formulation characteristics.

5 Other novel thiocationic lipids provided by the present invention are molecules possessing additional cationic groups which are incorporated into the molecule in the R³ position. In the preferred embodiments of this family of cationic lipids, the additional cationic 10 moieties are derived from the attachment of, for example, amino acids such as lysine, arginine, histidine or tryptophan.

The R³ is linked to the thiocationic lipid via A³, which may be -O-, -O-CO-, -CO-O-, -S-, -S-CO-, 15 -CO-S-, -O-CS-, -CS-O-, -CO-NH-, -NH-CO-, -CS-NH-, -NH-CS-, -NH-CO-O-, -NH-CO-NH-, -O-CO-NH-, or may be absent. The choice and/or need for a linker would be easily determined by one of skill in the art.

The thiocationic lipids of the present invention 20 can readily be synthesized using known methods. Typically, a lipid alcohol, such as that derived from glycerol, is converted to its bromo derivative using a brominating reagent such as a mixture of carbon tetrabromide and triphenyl phosphine. The bromo 25 derivative thus formed is then reacted with the sodium salt of an alkyl mercaptan, such as sodium thiomethoxide, so as to obtain the alkyl thioglycerol intermediate. Alkylation of this intermediate is carried out via refluxing in the presence of a haloalkyl 30 compound using an appropriate solvent, if necessary, to provide the cationic lipid as its halide salt.

Thiocationic Lipid-Biomolecule Conjugates

The thiocationic lipids of the present invention can also be in the form of compositions comprising the 35 thiocationic lipid covalently conjugated to biomolecules.

The biomolecule can be any organic compound which exhibits a desirable biological effect, and which is capable of retaining this biological effect after conjugation to the cationic lipid. Examples of 5 biomolecules include, but are not limited to, proteins, hormones, genes, polypeptides, oligonucleotides, nucleosides, drugs, antibiotics, antibodies, diagnostic imaging agents, and derivatives and analogues thereof. Covalent linkages between the thiocationic lipid and the 10 biomolecules can be accomplished using any known methods. See, for example, PCT WO 94/05624.

The biomolecule is preferably an oligonucleotide, and more preferably a phosphorothioate oligonucleotide for purposes of resistance to degradative nucleases. In 15 addition, the oligonucleotide may be RNA or DNA, but is more preferably DNA for purposes of resistance to RNases. Oligonucleotides which are useful in pharmaceutical formulations will typically have a nucleotide sequence that is either of interest or is 20 sufficiently complimentary to hybridize to a nucleotide sequence of interest. The oligonucleotide typically is capable of performing a biochemical function in receptor host cells and/or altering the operation of the cellular machinery. Examples of such functions are as 25 transfection or antisense agents.

Although appropriate oligonucleotide length depends entirely on the particular use for which the oligonucleotide is designed, certain generalizations are possible. If the oligonucleotide is to be used as an 30 antisense therapeutic agent, it will preferably be between about 12 and 50, and more preferably between about 15 and 30 nucleotides in length.

The oligonucleotides that may be used with the present invention include, but are not limited to, 35 naturally occurring nucleic acids, and modified nucleic acids such as those having phosphorothioate, methyl-phosphonate or phosphorodithioate internucleotide linkages. In addition, the biomolecule can be a

naturally occurring nucleoside, such as adenosine, guanosine, cytidine, thymidine and uridine or analogues thereof such as 5-fluorouridine, 5-alkyluridine, deazaguanosine, azaguanosine, azathymidine. The site of 5 attachment of a phosphorothioate oligonucleotide to the thiocationic lipids of the present invention may be via either the 5' or 3' terminus, the internucleotide linkages, the nucleoside bases or the backbone sugar moieties. Such linkages can be accomplished using any 10 known methods. For example, see Goodchild, et al., *Bioconjugate Chemistry* 1(3): 165-187 (1990). The cationic lipid may be attached via A³ and/or R³ to the 3'-OH or 5'-OH. Alternatively, the cationic lipid may be attached via A³ and/or R³ at any internucleotide 15 linkage, such as via the O or S atoms in the internucleotide phosphorothioate linkage. In addition, the cationic lipid may be attached to a base via A³ and/or R³ to an endocyclic ring C or N, or to an exocyclic N or O. It may also be attached via A³ and/or 20 R³ to the 1', 2' or 4' position of a sugar moiety.

II. Cationic Lipid Formulations

The pharmaceutical formulations employing the thiocationic lipids described herein may be composed of thiocationic lipid-biomolecule conjugates, or they may 25 be composed of cationic lipid-biomolecule complexes which are formed by mixing together the thiocationic lipids and the biomolecules described herein under conditions in which a stable association via ionic and/or hydrophobic interactions between the lipid and 30 the biomolecule is formed. In both cases, the thiocationic lipid-biomolecule conjugates/complexes are prepared and administered in a pharmacologically acceptable carrier. Examples of pharmacologically acceptable carriers include aqueous solutions such as 35 water, saline, buffers or carbohydrate solutions; and complex delivery systems such as liposomes, microspheres, or emulsions.

III. Liposome Formulations

The thiocationic lipid-containing biomolecule formulations of the present invention preferably consist of liposomes. Any of the aforementioned biomolecules 5 can be encapsulated into liposomes. In addition, numerous biomolecule-containing liposome formulations are described in the literature, and serve as examples of additional biomolecules suitable for encapsulation using the liposome formulations described herein.

10 Lipid aggregates can take the form of completely closed structures made up of a lipid bilayer containing an encapsulated aqueous volume (i.e. unilamellar liposomes), or they may contain more than one concentric lipid bilayer separated by an aqueous volume (i.e. 15 multilamellar liposomes). Each lipid bilayer is composed of two lipid monolayers, each of which has a hydrophobic (nonpolar) "tail" region and a hydrophilic (polar) "head" region. In the bilayer, the hydrophobic "tails" of the lipid monolayers orient toward the inside 20 of the bilayer, while the hydrophilic "heads" orient toward the outside of the bilayer. It is within the aqueous phase that the biomolecule becomes entrapped in the liposome, unless the biomolecule is in the form of a lipid-biomolecule conjugate, in which case the 25 biomolecule may become embedded within the bilayer.

Liposomes may be made by a variety of techniques known in the art. (See, for example, Bangham et al., J. Mol. Biol., 13: 238-252(1965)). These methods generally involve first dissolving and mixing the lipids in an 30 organic solvent, followed by evaporation. Then an appropriate amount of the aqueous phase is mixed with the lipid phase, and then allowed to incubate for a sufficient time for the liposomes to form. The aqueous phase will generally consist of the biomolecule in 35 suspension with other solutes, such as buffers or sugars.

In addition to the biomolecule to be encapsulated, the liposomes of the present invention are comprised of

the thiocationic lipids described herein alone, a mixture of thiocationic lipids described herein or the thiocationic lipids of the present invention combined with other known lipids, such as an anionic lipid (for example, phosphatidylglycerol, phosphaticid acid or a similar anionic phospholipid analog), or a neutral lipid (for example, phosphatidylcholine or phosphatidylethanolamine). The present liposomal formulations may further include a lysolipid, such as lysophosphatidylcholine, lysophosphatidylethanolamine, or a lyso form of a cationic lipid species.

The liposome can also include optional substituents, such as sterols, glycolipids, tissue or organ targeting substances such as antibodies or proteins, fatty acids, or any other natural or synthetic lipophilic or amphiphilic compounds.

Suitable sterols for inclusion into the liposomes include, but are not limited to, cholesterol and Vitamin D, and are included in the liposome formulations as stabilizers.

The molar ratio of thiocationic lipid to total lipid must be sufficient to result in the formation of a liposome with an overall positive charge. This amount will depend on the charge and amount of the encapsulated biomolecule, as well as the charge and amount of other constituents of the liposome. Generally, the liposome will contain from about 9:1 to 1:9 molar ratio of cationic lipid to total lipid, and preferably about 1:2 to 2:1. The molar ratio of total lipid to biomolecule is from about 200:1-100:1, and is preferably about 160:1.

IV. Liposome Formulations With Enhanced Efficacy

An important aspect of the present invention is the discovery that the efficacy of cationic lipid-biomolecule liposome formulations is enhanced by the presence of Vitamin D, and at least one pH sensitive amphiphilic lipid. Both ammonium ion and sulfonium ion-

containing cationic lipids are useful in such liposome formulations for the intracellular delivery of biomolecules.

The cationic lipid may be any of the thiocationic 5 lipids described herein, or any other known ammonium or sulfonium ion-containing cationic lipids. As described above, the cationic lipid may be used alone or in combination with other cationic, neutral or anionic lipids.

10 The Vitamin D may be Vitamin D₃ (also called "cholecalciferol"), or any analogue or derivative of Vitamin D which does not significantly diminish the overall efficacy-enhancing effects of Vitamin D, herein collectively referred to as "Vitamin D". Preferably, 15 underivatized Vitamin D₃ is employed.

Some amphiphiles have the ability to change their charge as a function of pH and are therefore "pH sensitive". For example, liposomal vesicles containing pH sensitive amphiphiles such as oleic acid and/or DOPE 20 can change their charge as a function of pH, while DOPC containing vesicles do not change their charge in a pH dependent fashion. The ability of an amphiphile to change its charge as a function of pH depends on the other constituents of the liposome. In particular, the 25 degree of alkyl chain saturation may have an effect. In addition, there may be ion-pairing interactions between the negative charges of the amphiphile, such as the negatively charged phosphate in DOPE, and the positively charged headgroups in the cationic lipids. This would 30 leave the positively charged amino group in the DOPE susceptible to a change in charge as a function of pH. (See Felgner et al., J. Bio. Chem. 269:1-12 (1994)).

The pH sensitivity of the amphiphile serves to enhance the fusogenicity of the liposomal vesicles with 35 endosomal membranes within the cell (Ropert et al., Biochem. Biophys. Res. Commun. 183(2): 879-85 (1992)). Suitable pH sensitive amphiphilic lipids include, but are not limited to DOPE and oleic acid. Preferably, the

pH sensitive amphiphile is oleic acid, but any lipophilic amphiphiles which are susceptible to a change in charge as a function of pH at or near physiological pH (around 6 to 7.5) after incorporation into the 5 liposome are suitable for use.

A particularly preferred liposome formulation for the intracellular delivery of oligonucleotides consists of cationic lipid:oleic acid:Vitamin D₃ in the molar ratio of 10:5:2. Other molar ratios can be designed to 10 maximize the efficacy of liposomal formulations consisting of different constituents and/or biomolecules. Such molar ratios can easily be determined using known techniques. See, for example, *Liposome Technologies*, CRC Press, publishers, Gregory Gregoriadis, ed. (1984).

15 V. Delivery of Pharmaceutical Formulations

The thiocationic lipids of the invention can be used in pharmaceutical formulations to deliver biomolecules by various routes and to various sites in the animal body to achieve a desired therapeutic effect. 20 These pharmaceutical formulations may consist of thiocationic lipid-biomolecule complexes and/or thiocationic lipid-biomolecule conjugates in any of the aforementioned pharmacologically acceptable carriers.

Local or systemic delivery of the formulation can 25 be achieved by administration comprising application or insertion of the formulation into body cavities, inhalation or insufflation of an aerosol, or by parenteral introduction, comprising intramuscular, intravenous, intradermal, peritoneal, subcutaneous and 30 topical administration.

Orally administered formulations may be in the form of solids, liquids, emulsions, suspensions, or gels, or preferably in dosage unit form, for example as tablets or capsules. Tablets may be compounded in combination 35 with other ingredients customarily used, such as talc, vegetable oils, polyols, gums, gelatin, starch, and other carriers.

Parenteral formulations intended for injection, either subcutaneously, intramuscularly, or intravenously, can be prepared either as liquids or solid forms for suspension in liquid prior to injection, 5 or as emulsions. Such preparations are sterile, and liquids to be injected intravenously should be isotonic. Suitable excipients are, for example, water, dextrose, saline, and glycerol.

The formulations may also be administered in 10 aerosol form to cavities of the body such as the nose, throat, or bronchial passages.

The ratio of biomolecule to the cationic lipid and the other compounding agents in these formulations will vary as the dosage form and amount requires.

15 Effective dosages of the formulations described herein depend on the biomolecule and its desired biological activity, as well as the particular formulation kinetics, composition, physical properties, desired therapeutic effect, subject weight, etc. Dosage 20 optimization can easily be performed using known method.

VI. Therapeutic Uses

The preferred therapeutic use of the biomolecule formulations described above is in the intracellular delivery of a therapeutic agent comprising a liposome-25 encapsulated antisense oligonucleotide. A particularly preferred therapeutic agent formulation which is useful in inhibiting HIV consists of a thiocationic lipid-containing liposomes as delivery vehicles of the phosphorothioate oligonucleotide given by SEQ. ID. NO. 30 1. This oligonucleotide is complementary to the mRNA sequence given by SEQ. ID. NO. 2 encoding the HIV *REV* protein. (See Peterson, et al., Published PCT Application No. WO 95/03407.)

Experimental Procedures

35 The present invention can be better understood by way of the following examples that are representative of

the preferred embodiments, but which are not to be construed as limiting the scope of the invention. All chemicals used herein were purchased from Aldrich Chemical Co., Milwaukee, WI, unless otherwise noted.

5

EXAMPLE I

Synthesis of Cationic Lipids

PART A: Synthesis of the Bromide Salt Form Of Domhytop

10 Step 1. Synthesis of 1,2-O-Dihexadecyl-3-bromo-1,2-propanediol

In a 250 ml round bottom flask equipped with a magnetic stir bar, 1.92 g (3.6 mmoles) of dihexadecylglycerol (Sigma Chemicals) was dissolved into 120 ml of toluene. To this solution were added 3.54 g (10.7 mmoles) of carbon tetrabromide and 2.80 g (10.7 mmoles) of triphenylphosphine and the reaction mixture was stirred overnight (18 hr) at room temperature. The yellow suspension was filtered and the filtrate concentrated on a rotary evaporator to afford a white solid. This residue was dissolved into toluene, washed once with saturated sodium chloride, dried over anhydrous magnesium sulfate and concentrated under vacuum on a rotary evaporator to afford 2.5 g of the crude product as a white powder. This crude product was purified by flash column chromatography on a silica gel 60 (E. Merck, Germany) column by sequential elution with 100 ml each of hexane, 1% ethyl acetate in hexane, 2% ethyl acetate in hexane and finally with 3% ethyl acetate in hexane. Fractions (8 ml) were collected and screened by thin-layer chromatography ("TLC") and those fractions that contained pure product (silica gel, 5% ethyl acetate in hexane, $R_f=0.59$) were pooled. The pooled fractions were concentrated under vacuum on a rotary evaporator to afford a quantitative yield of the 35 1,2-O-dihexadecyl-3-bromo-1,2-propanediol as a white powder.

Step 2. Synthesis of 1,2-O-Dihexadecyl-3-methylthio-1,2-propanediol

Racemic 1,2-O-dihexadecyl-3-bromo-1,2-propanediol (from Step 1), 2.0 g (3.3 mmoles), was dissolved into 100 ml of dry tetrahydrofuran in a 250 ml round bottom flask equipped with a magnetic stir bar. To this solution was added 2.33 g (33.2 mmoles) of sodium thiomethoxide powder and the reaction mixture was stirred overnight at room temperature. The reaction was monitored by TLC (silica gel, 5% ethyl acetate in hexane) and an additional 490 mg (7 mmoles) of sodium thiomethoxide was added to the reaction. After an additional 3 hr, the mixture was filtered and the filtrate was washed with 50 ml tetrahydrofuran. The combined filtrates were concentrated under vacuum using a rotary evaporator to afford a yellow residue. This residue was dissolved into 50 ml chloroform and the organic solution was washed twice with 25 ml of a concentrated solution of sodium bicarbonate. The organic phase was then dried over anhydrous magnesium sulfate and concentrated on a rotary evaporator under vacuum to afford the crude product as a pale yellow oily residue. The crude product was purified by column chromatography on a silica gel 60 (E. Merck, Germany) column using a step gradient of 0 to 10% ethyl acetate in hexane. The fractions collected were screened by TLC. Those fractions containing pure product were pooled and concentrated to afford 1,2-O-dihexadecyl-3-methylthio-1,2-propanediol in 90% yield.

Step 3. Synthesis of 1,2-O-Dihexadecyl-3-(S-methyl)-(6-hydroxyhexyl)-sulfonium bromide

Racemic 1,2-O-dihexadecyl-3-methylthio-1,2-propanediol (from Step 2), 1.0 g (1.75 mmoles), was dissolved into 120 ml toluene in a 250 round bottom flask equipped with a magnetic stir bar and a reflux condenser. To this solution was added 3.17 g (17.5

mmoles) of 6-bromohexanol and the solution heated at 135°C for 3 days. The brownish solution was then allowed to cool to room temperature and concentrated on a rotary evaporator to afford a brownish oily residue.

5 This residue was dissolved into 50 ml chloroform and washed twice with 30 ml of a saturated sodium chloride solution. The chloroform layer was then dried over magnesium sulfate. Upon removal of the magnesium sulfate by filtration, the solution was passed through a 10 bed of silica to remove the extremely polar impurities in the solution. This solution was next concentrated under vacuum to afford the crude product as a waxy residue. The crude product was purified by column chromatography using a silica gel 60 (E: Merck, Germany) 15 column and eluted sequentially first with 100 ml hexane, followed by 100 ml of 10% ethyl acetate in hexane and finally with 30% ethyl acetate in hexane. Fractions containing the product as determined by TLC were pooled and concentrated to afford the bromide salt of DOMHYTOP 20 as a low melting yellowish solid in 88% yield.

PART B: Synthesis of the Bromide Salt of Domcatop

Racemic 1,2-O-dihexadecyl-3-methylthio-1,2-propanediol (prepared as in Part A, Steps 1 and 2), 1.0 g (1.75 mmoles), was dissolved into 120 ml toluene in a 25 250 round bottom flask equipped with a magnetic stir bar and a reflux condenser. To this solution was added 3.41 g (17.5 mmoles) of 6-bromohexanoic acid and the solution heated at 135°C for 4 days. The brownish solution was then allowed to cool to room temperature and 30 concentrated on a rotary evaporator to afford a brownish oily residue. This residue was dissolved into 50 ml chloroform and passed through a bed of silica to remove the extremely polar impurities in the solution. The resulting solution was next washed with 30 ml of a 35 saturated sodium chloride solution. The chloroform layer was then dried over anhydrous magnesium sulfate. Upon removal of the magnesium sulfate by filtration, the

solution was concentrated under vacuum to afford the crude product as a yellowish oily residue. This crude product was purified by column chromatography using a silica gel 60 (E. Merck, Germany) column, eluting sequentially with 100 ml of hexane, followed by 10 ml of 10% ethyl acetate in hexane and finally with 30% ethyl acetate in hexane. Fractions from the 30% ethyl acetate in hexane eluates contained the product as determined by TLC and were pooled and concentrated to afford the bromide salt of DOMCATOP as a low melting yellowish solid in 42% yield.

PART C: Synthesis of the Bromide Salt of Obehytop

Step 1. Synthesis of 1-O-Octadecyl-2-O-benzyl-3-bromo-1,2-propanediol

In a 250 ml round bottom flask equipped with a magnetic stir bar, 2.00 g (4.6 mmoles) of 1-O-octadecyl-2-O-benzyl-glycerol (Bachem, Switzerland) was dissolved into 120 ml of toluene. To this solution were added 4.58 g. (13.8 mmoles) of carbon tetrabromide and 3.62 g. (13.8 mmoles) of triphenylphosphine and the reaction mixture stirred for 4 hours at room temperature. The yellow suspension was filtered and the filtrate concentrated on a rotary evaporator to afford a white solid. This residue was dissolved into 50 ml chloroform, washed twice with 30 ml saturated sodium bicarbonate, dried over anhydrous magnesium sulfate and concentrated under vacuum on a rotary evaporator to afford 2.5 g of the crude product as a white powder. This crude product was purified by flash column chromatography on a silica gel 60 (E. Merck, Germany) column by sequential elution with 100 ml each of hexane, 1% ethyl acetate in hexane, 2% ethyl acetate in hexane and finally with 3% ethyl acetate in hexane. Fractions collected were screened by TLC and those fractions that contained pure product (silica gel, 5% ethyl acetate in hexane, $R_f=0.56$) were pooled. The pooled fractions were concentrated under vacuum on a rotary evaporator to

afford a quantitative yield of the 1-O-octadecyl-2-O-benzyl-3-bromo-1,2-propanediol as a white powder.

Step 2. Synthesis of 1-O-Octadecyl-2-O-benzyl-3-methylthio-1,2-propanediol

5 Racemic 1-O-octadecyl-2-O-benzyl-3-bromo-1,2-propanediol, 1.99 g (4.0 mmoles), was dissolved into 100 ml of dry tetrahydrofuran in a 250 ml round bottom flask equipped with a magnetic stir bar. To this solution was added 2.8 g (40.0 mmoles) of sodium thiomethoxide powder
10 and the reaction mixture stirred for 4.5 hours at room temperature. The reaction was monitored by TLC (silica gel, 5% ethyl acetate in hexane; $R_f=0.51$). The mixture was filtered and the filtrate was washed with 50 ml tetrahydrofuran. The combined filtrates were
15 concentrated under vacuum using a rotary evaporator to afford a yellow residue. This residue was dissolved into 50 ml chloroform and the organic solution washed twice with 30 ml of a concentrated solution of sodium bicarbonate. The organic phase was then dried over
20 anhydrous magnesium sulfate and concentrated on a rotary evaporator under vacuum to afford the crude product as a pale yellow oily residue. This crude product was purified by chromatography on silica gel 60 (E. Merck, Germany) using a step gradient of 0 to 10% ethyl acetate
25 in hexane. The fractions collected were screened by TLC. Those fractions containing pure product (silica gel, 5% ethyl acetate in hexane, $R_f=0.51$) were pooled and concentrated to afford
1-O-octadecyl-2-O-benzyl-3-methylthio-1,2-propanediol in
30 90% yield.

Step 3. Synthesis of 1-O-Octadecyl-2-O-benzyl-3-(S-methyl-S-(6-hydroxyhexyl))-sulfonium bromide

35 Racemic 1-O-octadecyl-2-O-benzyl-3-methylthio-1,2-propanediol, 1.02 g (2.2 mmoles), was dissolved into 120 ml toluene in a 250 ml round bottom flask

equipped with a magnetic stir bar and a reflux condenser. To this solution was added 3.98 g. (22.0 mmoles) of 6-bromohexanol and the solution heated at 135°C for 3 days. The brownish solution was then 5 allowed to cool to room temperature and concentrated on a rotary evaporator to afford a brownish oily residue. This residue was dissolved into 50 ml chloroform and passed through a bed of silica to remove the extremely polar impurities in the solution. The resulting 10 solution was next washed twice with 30 ml of a saturated sodium bicarbonate solution, followed by extraction with 30 ml of a saturated sodium chloride solution. The chloroform layer was then dried over anhydrous magnesium sulfate. Upon removal of the magnesium sulfate by 15 filtration, the solution was concentrated under vacuum to afford the crude product as a yellowish oily residue. This crude product was purified by column chromatography using silica gel 60 (E. Merck, Germany), eluting sequentially with 100 ml of hexane, followed by 100 ml 20 of 10% ethyl acetate in hexane and finally with 30% ethyl acetate in hexane. Fractions containing the product as determined by TLC (silica gel, 30% ethyl acetate in hexane, $R_f=0.41$) were pooled and concentrated to afford the bromide salt of OBEHYTOP as a low melting 25 yellowish solid in 85% yield.

PART D: EXAMPLE 4: Synthesis of the Bromide Salt of Obecatop
Racemic 1-O-octadecyl-2-O-benzyl-3-methylthio-1,2-propanediol (prepared as in Part C, Steps 30 1 and 2), 1.0 g (1.75 mmoles), was dissolved into 120 ml toluene in a 250 round bottom flask equipped with a magnetic stir bar and a reflux condenser. To this solution was added 4.30 g (22.0 mmoles) of 6-bromohexanoic acid and the solution heated at 135°C 35 for 3 days. The brownish solution was then allowed to cool down to room temperature and concentrated on a rotary evaporator to afford a brownish oily residue.

This residue was dissolved into 50 ml chloroform and passed through a bed of silica to remove the extremely polar impurities in the solution. The resulting solution was next washed with 30 ml of a saturated 5 sodium chloride solution. The chloroform layer was then dried over anhydrous magnesium sulfate. Upon removal of the magnesium sulfate by filtration, the solution was concentrated under vacuum to afford the crude product as a yellowish oily residue. This crude product was 10 purified by column chromatography using silica gel 60 (E. Merck, Germany), eluting sequentially with 100 ml of hexane, followed by 100 ml of 10% ethyl acetate in hexane and finally with 30% ethyl acetate in hexane. Fractions containing the product as determined by TLC 15 (silica gel, 30% ethyl acetate in hexane, $R_f=0.36$) were pooled and concentrated to afford the bromide salt of OBECATOP as a low melting yellowish solid in 40% yield.

PART E: Synthesis of the Bromide Salt of Dodmecap

Step 1. Bromination of 1,2-dihexadecyloxy 20 glycerol:

1 g of 1,2-dihexadecyloxy glycerol was dissolved in 80 ml toluene in a 100 ml round bottom flask. To this solution, 1.84 g carbon tetrabromide and 1.46 g triphenylphosphine were added. The reaction mixture was 25 stirred at room temperature for 24 hr, and the progress of the reaction monitored by thin-layer-chromatography (5% ethyl acetate in hexane).

The resulting yellowish solid was filtered and the filtrate concentrated on a rotary evaporator and 30 dissolved in acetone. This step was repeated to isolate the product in the form of a white solid (yield 900 mg).

Step 2. Formation of 1,2-dihexadecyloxy-3- 35 dimethylamino glycerol.

900 mg of 3-bromo-1,2-dihexadecyloxy glycerol was dissolved in 30 ml chloroform in a 100 ml round bottom flask. 720 mg dimethylamine was added to yield an approximately 10 fold molar excess, and the reaction

mixture stirred at room-temperature overnight. The progress of the reaction was measured by thin-layer-chromatography (30% ethyl acetate in hexane).

The reaction mixture was transferred to a 5 separating funnel and washed twice with saturated aqueous sodium chloride. The organic layer was dried on magnesium sulfate and then filtered. The filtrate was concentrated on a rotary evaporator to yield 630 mg product.

10 Step 3. Formation of the Bromide Salt of Dodmecap
270 mg of 1,2-dihexadecyloxy-3-dimethylamino glycerol from Step 2, 0.628 g bromohexanoic acid and 0.271 g potassium carbonate were dissolved in 80 ml toluene in a 100 ml round bottom flask. The reaction 15 mixture was heated to 120°C in an oil bath and the conditions maintained overnight along with continuous stirring. The progress of the reaction was monitored using thin-layer-chromatography (30% ethyl acetate in hexane) and was shown to be complete in 20 hr.

20 The reaction mixture was then concentrated on a rotary evaporator. The white residue was dissolved in 30 ml chloroform and washed thrice in a separating funnel with 30 ml deionized water. The organic layer was dried using magnesium sulfate and filtered. The filtrate was 25 concentrated on a rotary evaporator and a white, waxy product obtained after precipitation with acetone. (yield 400 mg).

PART F: Synthesis of a Bromide Salt of Dodmehap

30 630 mg of 1,2-dihexadecyloxy-3-dimethylamino glycerol from Part E, Step 2, and 1.83 g bromohexanol were dissolved in 60 ml toluene in a 100 ml round bottom flask. The reaction mixture was heated to 110°C in an oil bath along with continuous stirring and the conditions maintained for 3 days. The progress of the reaction was 35 monitored using thin-layer-chromatography (30% ethyl acetate in hexane) and was shown to be complete after 3 days.

The reaction mixture was concentrated on a rotary evaporator. The residue was dissolved in 30 ml chloroform and extracted with 3 washes of saturated aqueous sodium bicarbonate in a separating funnel. The 5 organic layer was dried on magnesium sulfate and filtered. The filtrate was further concentrated on a rotary evaporator and purified on a Silica Gel 60 packed column (EM Sciences, Gibbstown, NJ). The product was eluted using a 30% solution of ethyl acetate in hexane. 10 Starting with 100% hexane, the concentration of ethyl acetate was gradually increased in each successive wash to 30%. (yield of product: 1.25 g).

EXAMPLE II

SYnthesis of a Domcatop-Oligonucleotide

15 ("Liponucleotide") Conjugate

PART A: Synthesis of the NHS Ester of the Bromide Salt of Domcatop

The bromide salt of DOMCATOP prepared in Example I Part B (130 mg, 0.17 mmole), was dissolved in 20 ml dry tetrahydrofuran, and 65 mg (0.56 mmole) of N-hydroxysuccinimide and 116 mg (0.56 mmole) of dicyclohexylcarbodiimide were added to the solution. The solution was stirred under nitrogen for 20 hours at room temperature. The dicyclohexyl urea formed upon 25 reaction was filtered off and the filtrate concentrated under reduced pressure to afford a residue that was dissolved into chloroform. This solution was extracted with saturated sodium bicarbonate, dried over magnesium sulfate and concentrated to afford a quantitative yield 30 of the NHS ester of DODMECAP.

PART B: Synthesis of a 5'-amino Terminated Oligonucleotide

Synthesis of a 5'-amino terminated oligonucleotide consisting of SEQ. ID. NO. 1 was carried 35 out using known standard phosphoramidite chemistry procedures and a commercially available automated

synthesizer. Cyanoethyl phosphoramidites of bases adenosine, guanosine, cytosine and tyrosine and an amino-linker phosphoramidite allowed for the synthesis of the oligonucleotide via automated synthesis on a 5 controlled pore glass solid support. The last step in the synthesis of the 5'-amino terminated oligonucleotides was the use of an aminolinker phosphoramidite (Applied Biosystems, Inc., Foster City, CA) so as to afford upon coupling the 5'-amino 10 terminated oligonucleotide. Deprotection of nucleoside bases, the O-cyanoethyl group and cleavage of the support bound oligonucleotide were performed in one step by treatment with ammonium hydroxide at 55°C for at least 15 hr. Concentration of the resulting ammonical 15 solution afforded the 5'-amino terminated oligonucleotide, which was dissolved in water and stored for subsequent use.

PART C: Coupling of the NHS Ester of Domcatop to the 20 5'-amino Terminated Oligonucleotide to Form a Liponucleotide

The phosphorothioate oligonucleotide prepared in Part B (2.2 mg in 300 μ l of water) was precipitated by addition of 33 μ l of 3M sodium acetate and 1 mL ethanol at -20°C for at least 1 hour. The precipitated 25 oligonucleotide was separated by centrifugation at 4°C for at least 30 minutes. The supernatant was removed, the oligonucleotide-containing pellet dried on a speed vacuum for 5 minutes and dissolved into 490 μ l of 0.25M HEPES solution (pH 8.1). To this solution 210 μ l of 30 pyridine and 280 μ l of a 25 mM solution of the thiocationic NHS ester in pyridine were added. The resulting mixture was vortexed and allowed to react at 55°C for at least 18 hours. The solution was transferred into a 10 ml tube, treated with 280 μ l of 3M sodium 35 acetate, 700 μ l of water and 7.9 ml of ethanol at -20°C for at least 2 hours. The resulting suspension was centrifuged at 17,000 rpm at 4°C for 1 hour and the

supernatant removed. The oligonucleotide-containing pellet obtained was dried and dissolved into 1 ml. water. This crude product was purified by reversed phase HPLC using a C8 radial pak column with a gradient 5 of increasing methanol concentration in 0.1M ammonium acetate (pH 7).

Fractions containing the liponucleotide were pooled, concentrated and the residue was dissolved into 1-2 ml. water, treated with 0.25 ml 3M sodium acetate 10 and 8 ml ethanol at -20°C overnight, to afford upon centrifugation a pellet of the liponucleotide.

EXAMPLE III

Synthesis of Liposome Formulations

The liposome preparations described below contained 15 indicated amounts of DOPE (Avanti Polar Lipids, Inc., Alabaster, AL); cholesterol (Avanti Polar Lipids, Inc., Alabaster, AL); Vitamin D₃ (Aldrich Chemical Co., Milwaukee, WI); oleic acid ("OA"; NuChek Prep Inc., Elysian, MN); and DODMECAP, DOMCATOP, DOMHYTOP, 20 DODMECAP, OBEHYTOP and OBECATOP prepared as described above. All ratios given are molar ratios. Unless otherwise indicated, the molar ratio of cationic lipid:titratable amphiphile:sterol used in the preparation of liposomes herein was 10:5:2. The term 25 "total lipids" refers to the sum of all of the components of the liposome given above. The phosphorothioate oligonucleotide referred to below is given by SEQ. ID. NO. 1.

A total of 80 μ moles of the total lipids in their 30 desired ratios was dissolved in chloroform, and then dried and rehydrated with an aqueous solution containing 1 ml of a 0.5 mM solution of the phosphorothioate oligonucleotide in phosphate buffered saline, pH 7.4. The preparations were then vortexed and allowed to come 35 to equilibration by overnight shaking at 37°C to allow the vesicles to form, and then freeze-thawed. Following this, the multilamellar liposomal vesicles thus formed

were extruded through polycarbonate filters of an appropriate pore size to obtain liposomes with a single bilayer. To remove any unencapsulated material, the liposomes were gel-filtered through a sizing gel column.

5 The total amount of encapsulated oligonucleotide was determined using a hybridization protection assay. (See Arnold, et al., PCT WO 89/02476.)

EXAMPLE IV

Cellular Uptake of Liposome Formulations

10 A total of 2×10^6 cells (U937 cells; ATCC, Rockville, MD) in 2 ml RPMI-1640 medium (BioWhittaker, Walkersville, MD) with 10% fetal bovine serum (GibcoBRL, Grand Island, NY) were plated in a 6-well tissue culture plate and incubated at 35°C in 5% CO₂. A 100 nM solution 15 of liposome-encapsulated or free oligonucleotide in phosphate buffered saline (pH 7.4) was introduced to the cells. After 48 hr, the cells were lysed, and the amount of oligonucleotide was determined as described in Example III.

20 The results indicated that liposomes which were prepared as described in Example III which contained the cationic lipids DODMECAP, DODMEHAP, DOMCATOP, DOMHYTOP, OBEHYTOP or OBECATOP in combination with oleic acid and Vitamin D₃ demonstrated similar oligonucleotide uptake 25 results.

EXAMPLE V

Viral Inhibition Assay

A total of 2.8×10^6 cells (Jurkat cells; ATCC) in 30 RPMI-1640 with 10% fetal calf serum were added to two 15 ml tubes in a total of 10 ml. The cells were centrifuged, the supernatant decanted, and cells were resuspended in 1 ml of the above medium. A 4.0 ml sample of retrovirus (HIV-1_{IIIB}) was added to one tube, and 4.0 ml of medium alone was added to the control. 35 The cells were incubated for 2 hr at 37°C in an

atmosphere of 5% CO₂. Free virus was washed from the cells and the cells were resuspended in 35 ml of medium.

The infected and control cells were placed in 125 μ l aliquots into a 96 well tissue culture plate.

5 Varying concentrations of liposomes prepared according to Example III, or free oligonucleotides, were added to the wells and the plates were incubated for 6 days at 37°C in an atmosphere of 5% CO₂. The p24 protein levels were determined by an antigen capture assay (Coulter 10 Immunology, Hialeah, FL; U.S. Pat. No. 4,886,742) using manufacturer's specifications and controls. The results are depicted in Figures 1, 2 and 3, with " - " representing the liposome with the oligonucleotide, " - - " representing the control liposome with no 15 oligonucleotide and " - - " representing the free oligonucleotide.

In Figure 1, results are presented for liposomes prepared using the thiocationic lipid DOMCATOP with or without the oligonucleotide, and for the oligonucleotide 20 alone. As shown, the liposome containing the oligonucleotide effectively inhibited viral replication as demonstrated by a significant reduction in p24 levels.

In Figure 2, the results are presented with the 25 ammonium ion-containing lipid DODMECAP. As shown, no inhibition in viral replication was observed.

In Figure 3, the results are presented for liposomes prepared using the ammonium ion-containing lipid DODMEHAP with either Vitamin D₃ or cholesterol as 30 the sterol. As shown, the Vitamin D₃-containing liposomes were unexpectedly more effective at inhibiting viral replication than their cholesterol-containing equivalents.

EXAMPLE VI

35 Cellular Metabolic Activity Assay

To determine the effects on cellular metabolic activity as a measure of the toxicity of the different

liposome formulations, an XTT assay was performed on the infected cells from Example V as follows: A 1 mg/ml XTT (2,3-bis[2-methoxy-4-nitro-S-sulfophenyl]-2H-tetrazolium-S-carboxanilide inner salt; Sigma Chemical Co., St. Louis, MO) solution in cell medium was prepared. To this, 5 μ l of 5 mM phenazine methosulfate (Sigma Chemical Co.) per ml of XTT solution was added. A 50 μ l aliquot of the resultant mixture was added to each well, and the plates were incubated for 4 hr at 37°C in an atmosphere of 5% CO₂. Then, 15 μ l of Triton X-100 (Sigma Chemical Co.) was added to each well, and the optical density (O.D.) at 450-650 nm dual absorbancy was read. Corrected O.D. measurements were determined by subtracting the appropriate control levels.

As depicted in Figure 4, using increasing concentrations of liposomes prepared as described in Example III, liposomes with the ammonium ion-containing lipid (DODMEHAP) began to show signs of toxicity (as evidenced by a decrease in O.D.) at much lower concentrations than the liposomes with the equivalent sulfonium ion-containing lipid (DOMHYTOP).

Other aspects, uses and advantages of the present invention will be apparent to those skilled in the art upon review of the present disclosure. Those skilled in the art also will recognize that numerous changes can be made to the structures and methods described herein without departing from the spirit of the invention. The following claims therefore set forth the scope of the present invention, which claims are not to be limited by the specific embodiments described above in the specification.

SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT: Gen-Probe Incorporated

(ii) TITLE OF INVENTION: THIOCATIONIC LIPIDS,
PHARMACEUTICAL
COMPOSITIONS AND METHODS
OF USE THEREOF

(iii) NUMBER OF SEQUENCES: 2

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Lyon & Lyon
(B) STREET: 633 West Fifth Street,
Suite 4700
(C) CITY: Los Angeles
(D) STATE: California
(E) COUNTRY: USA
(F) ZIP: 90071-2066

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: 3.5" Diskette, 1.44
Mb
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: MS-DOS (Version 6.22)
(D) SOFTWARE: Word Perfect (Version
5.1)

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

Prior applications total,
including application
described below: six

(A) APPLICATION NUMBER: 08/482,497
(B) FILING DATE: 06/07/95
(C) APPLICATION NUMBER: 08/480,203
(D) FILING DATE: 06/07/95
(E) APPLICATION NUMBER: 08/480,204
(F) FILING DATE: 06/07/95
(G) APPLICATION NUMBER: 08/482,430
(H) FILING DATE: 06/07/95
(I) APPLICATION NUMBER: 08/482,305
(J) FILING DATE: 06/07/95
(K) APPLICATION NUMBER: 08/480,622
(L) FILING DATE: 06/07/95

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Schneider,
Carol A.

(B) REGISTRATION NUMBER: 34,923

(C) REFERENCE/DOCKET NUMBER: 219/080-PCT

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (213) 489-1600
(B) TELEFAX: (213) 955-0440
(C) TELEX:

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

CTTCGGGCCT GTCGGGTCCC CTCGGG 26

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:


(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

CCCGAGGGGA CCCGACAGGC CCGAAG 26

Claims

1. A compound for facilitating the transport of biomolecules into cells of the general formula:



and optical isomers and/or salts thereof wherein:

A^1 and A^2 are the same or different and are $-\text{O}-\text{CO}-$, $-\text{O}-$, $-\text{S}-\text{CO}-$ or $-\text{S}-$;

A^3 is $-\text{O}-$, $-\text{O}-\text{CO}-$, $-\text{CO}-\text{O}-$, $-\text{S}-$, $-\text{S}-\text{CO}-$, $-\text{CO}-\text{S}-$, $-\text{O}-\text{CS}-$, $-\text{CS}-\text{O}-$, $-\text{CO}-\text{NH}-$, $-\text{NH}-\text{CO}-$, $-\text{CS}-\text{NH}-$, $-\text{NH}-\text{CS}-$, $-\text{NH}-\text{CO}-\text{O}-$, $-\text{NH}-\text{CO}-\text{NH}-$, $-\text{O}-\text{CO}-\text{NH}-$, or is absent;

R^1 and R^2 are the same or different and are H , or C_1 to C_{23} saturated or partially unsaturated alkyl or aralkyl, with the proviso that at least one of R^1 and R^2 is not H ;



R^3 is a C_1 to C_{12} alkyl, aralkyl, alkaryl, heterocyclyl or heteroaryl; or

R^3 is an amino acid, a dipeptide, a tripeptide, a tetrapeptide or a pentapeptide; or

R^3 is $-[(\text{CH}_2)_p-\text{NR}^4]_q-\text{R}^4$,

$- (\text{CH}_2)_p-\text{NR}^4_3+$,

5



wherein p is 1 to 5, q is 0 to 4, and R⁴ is H or a C₁ to C₄ alkyl and m, n and o are 0 to 8 with the provisos that m ≥ 1 and (m + n + o) ≥ 3.

2. The compound of claim 1 wherein

5 a) A¹ and A² are each independently selected from the group consisting of -O-, -O-CO-, and -S-;

b) R¹ and R² are each independently selected from the group consisting of

10 i) a saturated or partially unsaturated C₂-C₂₄ hydrocarbon group,

ii) benzyl, and

iii) phenethyl;

c) A³ is selected from the group consisting of -O-, -CO-O-, -S-, and -NH-CO-, or is absent;

15 d) R³ is selected from the group consisting of

i) saturated or partially unsaturated C₁-C₁₂ alkyl or aralkyl,

ii) -[(CH₂)_p-NR⁴]_q-R⁴ wherein p is 3-4, q is from 0-4 and R⁴ is H,

20 iii) -(CH₂)_p-NR⁴₃⁺ wherein p is 2-3 and R³ is methyl, and

iv)
$$\begin{array}{c} \text{NH} \\ \parallel \\ -\text{C}-\text{NR}^4_2 \end{array}$$
 wherein R⁴ is methyl.

25 3. The compound of claim 2 wherein,

a) R¹ and R² are each independently selected from the group consisting of

i) a saturated or partially unsaturated C₂-C₂₄ alkyl group, and

ii) benzyl;

b) A³ is -O-;

c) n = 0-8;

d) o = 0-8;

e) m = 1 to 23; and

35 f) R³ is -[(CH₂)_p-NR⁴]_q-R⁴.

4. The compound of claim 3 wherein

a) R¹ and R² are each independently selected from the group consisting of

5 i) a saturated or partially unsaturated C₁₈ alkyl group,

ii) a saturated or partially unsaturated C₁₆ alkyl group, and

iii) benzyl,

and m = 6.

10 5. The compound of claim 4 wherein

a) A¹ and A² are both -O-;

b) R¹ is a saturated C₁₆ or C₁₈ alkyl group and R² is a benzyl group;

c) n = 0;

15 d) o = 0;

e) q = 0; and

f) R⁴ is H.

6. The compound of claim 2 wherein

a) R¹ and R² are each independently selected from the group consisting of

20 i) a saturated or partially unsaturated C₂-C₂₄ alkyl group, and

ii) benzyl;

b) A³ is -CO-O-;

25 c) n = 0-8;

d) o = 0-8;

e) m = 1 to 23; and

g) R³ is -[(CH₂)_p-NR⁴]_q-R⁴.

7. The compound of claim 6 wherein

30 a) R¹ and R² are each independently selected from the group consisting of

i) a saturated or partially unsaturated C₁₈ alkyl group,

ii) a saturated or partially unsaturated C₁₆ alkyl group, and
 iii) benzyl,
 and m = 5.


5 8. The compound of claim 7 wherein

- a) A¹ and A² are both -O-;
- b) R¹ is a saturated C₁₆ or C₁₈ alkyl group and R² is a benzyl group;
- c) n = 0;
- 10 d) o = 0;
- e) q = 0; and
- f) R⁴ is H.

9. The compound of claim 4 wherein

- a) A¹ and A² are both -O-;
- b) R¹ and R² are each a saturated C₁₆ or C₁₈ alkyl group;
- c) n = 0;
- d) o = 0;
- e) q = 0; and
- 20 f) R⁴ is H.

10. A method for introducing at least one biomolecule into a cell, said method comprising the steps of
 a) providing a pharmaceutical composition comprising a biomolecule and at least one thiocationic lipid of the
 25 general formula:



30 and optical isomers and/or salts thereof wherein:

A¹ and A² are the same or different and are -O-CO-,
 35 -O-, -S-CO- or -S-;

A^3 is $-O-$, $-O-CO-$, $-CO-O-$, $-S-$, $-S-CO-$, $-CO-S-$, $-O-CS-$, $-CS-O-$, $-CO-NH-$, $-NH-CO-$, $-CS-NH-$, $-NH-CS-$, $-NH-CO-O-$, $-NH-CO-NH-$, $-O-CO-NH-$, or is absent;


5 R^1 and R^2 are the same or different and are H, or C_1 to C_{23} saturated or partially unsaturated alkyl or aralkyl, with the proviso that at least one of R^1 and R^2 is not H;

R^3 is a C_1 to C_{12} alkyl, aralkyl, alkaryl, heterocyclyl or heteroaryl; or

10 R^3 is an amino acid, a dipeptide, a tripeptide, a tetrapeptide or a pentapeptide; or

R^3 is $-[(CH_2)_p-NR^4]_q-R^4$,

$- (CH_2)_p-NR^4_3^+$,



10 wherein p is 1 to 5, q is 0 to 4, and R^4 is H or a C_1 to C_4 alkyl and m, n and o are 0 to 8 with the provisos that $m \geq 1$ and $(m + n + o) \geq 3$, and

15 b) contacting the cell with said pharmaceutical formulation whereby said thiocationic lipid facilitates the entry of one or more of said biomolecules into said cell.

11. The method of claim 10 wherein said thiocationic lipid is contained in a liposome.

12. The method of claim 10 wherein, in said 20 thiocationic lipid,

a) A^1 and A^2 are each independently selected from the group consisting of: $-O-$, $-O-CO-$, and $-S-$;

b) R^1 and R^2 are each independently selected from the group consisting of

i) a saturated or partially unsaturated C_2-C_{24} hydrocarbon group,

5 ii) benzyl, and

iii) phenethyl;

c) A^3 is selected from the group consisting of $-O-$, $-CO-O-$, $-S-$, and $-NH-CO-$, or is absent;

d) R^3 is selected from the group consisting of

10 i) saturated or partially unsaturated C_1-C_{12} alkyl or aralkyl,

ii) $-[(CH_2)_p-NR^4]_q-R^4$ wherein p is 3-4, q is from 0-4 and R^4 is H,

15 iii) $-(CH_2)_p-NR^4_3^+$ wherein p is 2-3 and R^3 is methyl, and

iv) $\begin{array}{c} NH \\ || \\ -C-NR^4_2 \end{array}$ wherein R^4 is methyl.

13. The method of claim 12 wherein, in said
20 thiocationic lipid,

a) R^1 and R^2 are each independently selected from the group consisting of

i) a saturated or partially unsaturated C_2-C_{24} alkyl group, and

25 ii) benzyl;

b) A^3 is $-O-$;

c) $n = 0-8$;

d) $o = 0-8$;

e) $m = 1$ to 23; and

30 f) R^3 is $-[(CH_2)_p-NR^4]_q-R^4$.

14. The method of claim 13 wherein, in said thiocationic lipid,

a) R^1 and R^2 are each independently selected from the group consisting of

45

- i) a saturated or partially unsaturated C_{18} alkyl group,
- ii) a saturated or partially unsaturated C_{16} alkyl group, and
- 5 iii) benzyl,
and $m = 6$.

15. The method of claim 14 wherein, in said thiocationic lipid,

- a) A^1 and A^2 are both $-O-$;
- 10 b) R^1 is a saturated C_{16} or C_{18} alkyl group and R^2 is a benzyl group;
- c) $n = 0$;
- d) $o = 0$;
- e) $q = 0$; and
- 15 f) R^4 is H.

16. The method of claim 12 wherein, in said thiocationic lipid

- a) R^1 and R^2 are each independently selected from the group consisting of
 - 20 i) a saturated or partially unsaturated C_2-C_{24} alkyl group, and
 - ii) benzyl;
- b) A^3 is $-CO-O-$;
- c) $n = 0-8$;
- 25 d) $o = 0-8$;
- e) $m = 1$ to 23 ; and
- g) R^3 is $-[(CH_2)_p-NR^4]_q-R^4$.

17. The method of claim 16 wherein, in said thiocationic lipid

- 30 a) R^1 and R^2 are each independently selected from the group consisting of
 - i) a saturated or partially unsaturated C_{18} alkyl group,

ii) a saturated or partially unsaturated C₁₆ alkyl group, and
iii) benzyl,
and m = 5.

5 18. The method of claim 17 wherein, in said thiocationic lipid

- a) A¹ and A² are both -O-;
- b) R¹ is a saturated C₁₆ or C₁₈ alkyl group and R² is a benzyl group;
- 10 c) n = 0;
- d) o = 0;
- e) q = 0; and
- f) R⁴ is H.

19. The method of claim 14 wherein, in said thiocationic lipid


- a) A¹ and A² are both -O-;
- b) R¹ and R² are each a saturated C₁₆ or C₁₈ alkyl group;
- 20 c) n = 0;
- d) o = 0;
- e) q = 0; and
- f) R⁴ is H.

20. The method of claim 10 wherein said biomolecule is an oligonucleotide.

25 21. A method for introducing an oligonucleotide within an animal cell comprising the steps:

- a) providing a pharmaceutical composition containing said oligonucleotide and a thiocationic lipid, and
- 30 b) contacting said cell with said pharmaceutical composition whereby said thiocationic lipid facilitates the entry of said oligonucleotide within said cell.

22. A composition comprising a conjugate of at least one biomolecule and at least one thiocationic lipid of the general formula:



and optical isomers and/or salts thereof wherein:

A^1 and A^2 are the same or different and are $-\text{O}-\text{CO}-$, $-\text{O}-$, $-\text{S}-\text{CO}-$ or $-\text{S}-$;

15 A^3 is $-\text{O}-$, $-\text{O}-\text{CO}-$, $-\text{CO}-\text{O}-$, $-\text{S}-$, $-\text{S}-\text{CO}-$, $-\text{CO}-\text{S}-$, $-\text{O}-\text{CS}-$, $-\text{CS}-\text{O}-$, $-\text{CO}-\text{NH}-$, $-\text{NH}-\text{CO}-$, $-\text{CS}-\text{NH}-$, $-\text{NH}-\text{CS}-$, $-\text{NH}-\text{CO}-\text{O}-$, $-\text{NH}-\text{CO}-\text{NH}-$, $-\text{O}-\text{CO}-\text{NH}-$, or is absent;



20 R^1 and R^2 are the same or different and are H, or C_1 to C_{23} saturated or partially unsaturated alkyl or aralkyl, with the proviso that at least one of R^1 and R^2 is not H;

25 R^3 is a C_1 to C_{12} alkyl, aralkyl, alkaryl, heterocyclyl or heteroaryl; or

R^3 is an amino acid, a dipeptide, a tripeptide, a tetrapeptide or a pentapeptide; or

R^3 is $-[(\text{CH}_2)_p-\text{NR}^4]_q-\text{R}^4$,

25 $- (\text{CH}_2)_p-\text{NR}^4_3^+$,



10 wherein p is 1 to 5, q is 0 to 4, and R^4 is H or a C_1 to C_4 alkyl and m, n and o are 0 to 8, with the provisos that $m \geq 1$ and $(m + n + o) \geq 3$.

23. The composition of claim 22 wherein said biomolecule is an oligonucleotide.

24. The composition of claim 22 wherein, in said thiocationic lipid portion of said conjugate,

5 a) A^1 and A^2 are each independently selected from the group consisting of: -O-, -O-CO-, and -S-;

10 b) R^1 and R^2 are each independently selected from the group consisting of

- i) a saturated or partially unsaturated C_2-C_{24} hydrocarbon group,
- ii) benzyl, and
- iii) phenethyl;

15 c) A^3 is selected from the group consisting of -O-, -CO-O-, -S-, and -NH-CO-, or is absent;

20 d) R^3 is selected from the group consisting of

- i) saturated or partially unsaturated C_1-C_{12} alkyl or aralkyl,
- ii) $-[(CH_2)_p-NR^4]_q-R^4$ wherein p is 3-4, q is from 0-4 and R^4 is H,
- iii) $-(CH_2)_p-NR^4_3^+$ wherein p is 2-3 and R^3 is methyl, and
- iv) $\begin{array}{c} NH \\ || \\ -C-NR^4_2 \end{array}$ wherein R^4 is methyl.

25 25. The composition of claim 24 wherein, in said thiocationic lipid portion of said conjugate,

30 a) R^1 and R^2 are each independently selected from the group consisting of

- i) a saturated or partially unsaturated C_2-C_{24} alkyl group, and
- ii) benzyl;

35 b) A^3 is -O-;

 c) n = 0-8;

 d) o = 0-8;

 e) m = 1 to 23; and

 f) R^3 is $-[(CH_2)_p-NR^4]_q-R^4$.

26. The composition of claim 25 wherein, in said thiocationic lipid portion of said conjugate,

a) R^1 and R^2 are each independently selected from the group consisting of

5 i) a saturated or partially unsaturated C_{18} alkyl group,

ii) a saturated or partially unsaturated C_{16} alkyl group, and

iii) benzyl,

10 and $m = 6$.

27. The composition of claim 26 wherein, in said thiocationic lipid portion of said conjugate,

a) A^1 and A^2 are both $-O-$;

15 b) R^1 is a saturated C_{16} or C_{18} alkyl group and R^2 is a benzyl group;

c) $n = 0$;

d) $o = 0$;

e) $q = 0$; and

f) R^4 is H.

20 28. The composition of claim 24 wherein, in said thiocationic lipid portion of said conjugate,

a) R^1 and R^2 are each independently selected from the group consisting of

25 i) a saturated or partially unsaturated C_2-C_{24} alkyl group, and

ii) benzyl;

b) A^3 is $-CO-O-$;

c) $n = 0-8$;

d) $o = 0-8$;

30 e) $m = 1$ to 23; and

g) R^3 is $-[(CH_2)_p-NR^4]_q-R^4$.

29. The composition of claim 28 wherein, in said thiocationic lipid portion of said conjugate,

a) R^1 and R^2 are each independently selected from the group consisting of

i) a saturated or partially unsaturated C_{18} alkyl group,

5 ii) a saturated or partially unsaturated C_{16} alkyl group, and

iii) benzyl,

and $m = 5$.

30. The composition of claim 29 wherein, in said
10 thiocationic lipid portion of said conjugate,

a) A^1 and A^2 are both $-O-$;

b) R^1 is a saturated C_{16} or C_{18} alkyl group and R^2 is a benzyl group;

c) $n = 0$;

15 d) $o = 0$;

e) $q = 0$; and

f) R^4 is H.

31. The composition of claim 26 wherein, in said thiocationic lipid portion of said conjugate,

20 a) A^1 and A^2 are both $-O-$;

b) R^1 and R^2 are each a saturated C_{16} or C_{18} alkyl group;

c) $n = 0$;

d) $o = 0$;

25 e) $q = 0$; and

f) R^4 is H.

32. The composition of claim 23 wherein said oligonucleotide and said thiocationic lipid comprise two moieties joined by a covalent linkage to form said
30 conjugate.


33. The composition of claim 32 wherein said linkage is formed by reaction of a N-hydroxysuccinate group of one of said moieties with an amino group of the other moiety.

34. The composition of claim 23 further comprising said conjugate contained in a pharmaceutically acceptable formulation.

35. A composition comprising a conjugate of at least 5 one biomolecule and at least one thiocationic lipid.

36. A therapeutic composition comprising a conjugate of at least one oligonucleotide and at least one thiocationic lipid.

37. A method for introducing at least one biomolecule 10 into a cell, said method comprising the steps of
a) providing a pharmaceutical composition containing a conjugate comprising at least one biomolecule joined to at least one thiocationic lipid of the general formula:



and optical isomers and/or salts thereof wherein:

A^1 and A^2 are the same or different and are $-\text{O}-\text{CO}-$, $-\text{O}-$, $-\text{S}-\text{CO}-$ or $-\text{S}-$;

25 A^3 is $-\text{O}-$, $-\text{O}-\text{CO}-$, $-\text{CO}-\text{O}-$, $-\text{S}-$, $-\text{S}-\text{CO}-$, $-\text{CO}-\text{S}-$, $-\text{O}-\text{CS}-$, $-\text{CS}-\text{O}-$, $-\text{CO}-\text{NH}-$, $-\text{NH}-\text{CO}-$, $-\text{CS}-\text{NH}-$, $-\text{NH}-\text{CS}-$, $-\text{NH}-\text{CO}-\text{O}-$, $-\text{NH}-\text{CO}-\text{NH}-$, $-\text{O}-\text{CO}-\text{NH}-$, or is absent;

30 R^1 and R^2 are the same or different and are H , or C_1 to C_{23} saturated or partially unsaturated alkyl or aralkyl, with the proviso that at least one of R^1 and R^2 is not H ;


R^3 is a C_1 to C_{12} alkyl, aralkyl, alkaryl, heterocyclyl or heteroaryl; or

R^3 is an amino acid, a dipeptide, a tripeptide, a tetrapeptide or a pentapeptide; or

R³ is - [(CH₂)_p-NR⁴]_q-R⁴,

- (CH₂)_p-NR⁴₃⁺,

5



10 wherein p is 1 to 5, q is 0 to 4, and R⁴ is H or a C₁ to C₄ alkyl; and m, n and o are 0 to 8 with the provisos that m ≥ 1 and (m + n + o) ≥ 3; and

15 b) contacting said pharmaceutical composition with said cell to facilitate delivery of said biomolecule within said cell.

38. The method of claim 2 wherein said conjugate is contained in a liposome.

39. The method of claim 2 wherein, in said thiocationic lipid portion of said conjugate,

20 a) A¹ and A² are each independently selected from the group consisting of: -O-, -O-CO-, and -S-;

b) R¹ and R² are each independently selected from the group consisting of

25 i) a saturated or partially unsaturated C₂-C₂₄ hydrocarbon group,

ii) benzyl, and

iii) phenethyl;

c) A³ is selected from the group consisting of -O-, -CO-O, -S-, and -NH-CO-, or is absent;

30 d) R³ is selected from the group consisting of i) saturated or partially unsaturated C₁-C₁₂ alkyl or aralkyl,

ii) $-(CH_2)_p-NR^4]_q-R^4$ wherein p is 3-4, q is from 0-4 and R⁴ is H,

iii) $-(CH_2)_p-NR^4_3$ wherein p is 2-3 and R₃ is methyl, and

5

NH

iv) $\begin{array}{c} \text{NH} \\ \parallel \\ -C-NR^4_2 \end{array}$ wherein R⁴ is methyl.

40. The method of claim 39 wherein, in said thiocationic lipid portion of said conjugate,

10 a) R¹ and R² are each independently selected from the group consisting of

i) a saturated or partially unsaturated C₂-C₂₄ alkyl group, and

ii) benzyl;

15 b) A³ is -O-;

c) n = 0-8;

d) o = 0-8;

e) m = 1 to 23; and

f) R³ is $-(CH_2)_p-NR^4]_q-R^4$.

20 41. The method of claim 40 wherein, in said thiocationic lipid portion of said conjugate,

a) R¹ and R² are each independently selected from the group consisting of

i) a saturated or partially unsaturated C₁₈ alkyl group,

25 ii) a saturated or partially unsaturated C₁₆ alkyl group, and

iii) benzyl,

and m = 6.

30 42. The method of claim 41 wherein, in said thiocationic lipid portion of said conjugate,

a) A¹ and A² are both -O-;

b) R¹ is a saturated C₁₆ or C₁₈ alkyl group and R² is a benzyl group;

35 c) n = 0;

- d) $\sigma = 0$
- e) $q = 0$; and
- f) R^4 is H.

43. The method of claim 39 wherein, in said
5 thiocationic lipid portion of said conjugate,

- a) R^1 and R^2 are each independently selected from the group consisting of
 - i) a saturated or partially unsaturated C_2-C_{24} alkyl group, and
 - 10 ii) benzyl;
- b) A^3 is $-CO-O-$;
- c) $n = 0-8$;
- d) $\sigma = 0-8$;
- e) $m = 1$ to 23; and
- 15 g) R^3 is $-[(CH_2)_p-NR^4]_q-R^4$.

44. The method of claim 43 wherein, in said thiocationic lipid portion of said conjugate,

- a) R^1 and R^2 are each independently selected from the group consisting of
 - i) a saturated or partially unsaturated C_{18} alkyl group,
 - 20 ii) a saturated or partially unsaturated C_{16} alkyl group, and
 - iii) benzyl,
- 25 and $m = 5$.

45. The method of claim 44 wherein, in said thiocationic lipid portion of said conjugate,

- a) A^1 and A^2 are both $-O-$;
- b) R^1 is a saturated C_{16} or C_{18} alkyl group and R^2 is
30 a benzyl group;
- c) $n = 0$;
- d) $\sigma = 0$;
- e) $q = 0$; and
- f) R^4 is H.

46. The method of claim 41 wherein, in said thiocationic lipid portion of said conjugate,

- a) A^1 and A^2 are both -O-;
- b) R^1 and R^2 are each a saturated C_{16} or C_{18} alkyl group;
- 5 c) $n = 0$;
- d) $\sigma = 0$;
- e) $q = 0$; and
- f) R^4 is H.

10 47. The method of claim 37 wherein said biomolecule is an oligonucleotide.


48. The method of claim 47 wherein said oligonucleotide and said thiocationic lipid comprise two moiieties joined by a covalent linkage to form said 15 conjugate.

49. The method of claim 48 wherein said linkage is formed by reaction of a N-hydroxysuccinate group of one of said moieties with an amino group of the other moiety.

50. A composition for introducing at least one 20 biomolecule into a cell comprising: a liposome, said liposome comprising an ammonium or sulfonium ion-containing lipid, a Vitamin D derivative, a pH sensitive amphiphile, and a biomolecule.




51. The composition of claim 50 wherein said 25 biomolecule is an oligonucleotide.

52. The composition of claim 50 wherein said lipid has the general structure



and optical isomers and/or salts thereof wherein:

A¹ and A² are the same or different and are -O-CO-,
 10 -O-, -S-CO- or -S-;
 A³ is -O-, -O-CO-, -CO-O-, -S-, -S-CO-, -CO-S-, -O-CS-,
 -CS-O-, -CO-NH-, -NH-CO-, -CS-NH-, -NH-CS-, -NH-CO-O-,
 -NH-CO-NH-, -O-CO-NH-, or is absent;
 R¹ and R² are the same or different and are H, or C₁ to
 15 C₂₃ saturated or partially unsaturated alkyl or aralkyl,
 with the proviso that at least one of R¹ and R² is not H;
 R³ is a C₁ to C₁₂ alkyl, aralkyl, alkaryl, heterocyclyl
 or heteroaryl; or
 R³ is an amino acid, a dipeptide, a tripeptide, a
 20 tetrapeptide or a pentapeptide; or
 R³ is -[(CH₂)_p-NR⁴]_q-R⁴,



10 wherein p is 1 to 5, q is 0 to 4, and R⁴ is H or a C₁ to C₄ alkyl and m, n and o are 0 to 8, with the provisos
 that m ≥ 1 and (m + n + o) ≥ 3.

53. The composition of claim 52 wherein the molar ratio of lipid to Vitamin D derivative to amphiphile in
 15 said liposome is about 10:5:2.

54. The composition of claim 53 wherein said Vitamin D derivative is Vitamin D₃.

55. The composition of claim 54 wherein said amphiphile is selected from the group consisting of an 5 aliphatic carboxylic acid and DOPE.

56. The composition of claim 55 wherein said carboxylic acid is oleic acid.

57. The composition of claim 52 wherein, in said lipid,

10 a) A¹ and A² are each independently selected from the group consisting of: -O-, -O-CO-, and -S-;

b) R¹ and R² are each independently selected from the group consisting of

15 i) a saturated or partially unsaturated C₂-C₂₄ hydrocarbon group,

ii) benzyl, and

iii) phenethyl;

c) A³ is selected from the group consisting of -O-, -CO-O, -S-, and -NH-CO-, or is absent;

20 d) R³ is selected from the group consisting of

i) saturated or partially unsaturated C₁-C₁₂ alkyl or aralkyl,

ii) -[(CH₂)_p-NR⁴]_q-R⁴ wherein p is 3-4, q is from 0-4 and R⁴ is H,

25 iii) -(CH₂)_p-NR⁴₃⁺ wherein p is 2-3 and R³ is methyl, and

iv)
$$\begin{array}{c} \text{NH} \\ \parallel \\ -\text{C}-\text{NR}^4_2 \end{array}$$
 wherein R⁴ is methyl.

30 58. The composition of claim 57 wherein, in said lipid,

a) R¹ and R² are each independently selected from the group consisting of

- i) a saturated or partially unsaturated C₂-C₂₄ alkyl group, and
- ii) benzyl;
- b) A³ is -O-;
- 5 c) n = 0-8;
- d) o = 0-8;
- e) m = 1 to 23; and
- f) R³ is -[(CH₂)_p-NR⁴]_q-R⁴.

59. The composition of claim 58 wherein, in said
10 lipid,

- a) R¹ and R² are each independently selected from the group consisting of
 - i) a saturated or partially unsaturated C₁₈ alkyl group,
 - 15 ii) a saturated or partially unsaturated C₁₆ alkyl group, and
 - iii) benzyl,
- and m = 6.

60. The composition of claim 59 wherein, in said
20 lipid,

- a) A¹ and A² are both -O-;
- b) R¹ is a saturated C₁₆ or C₁₈ alkyl group and R² is a benzyl group;
- c) n = 0;
- 25 d) o = 0;
- e) q = 0; and
- f) R⁴ is H.

61. The composition of claim 57 wherein, in said lipid,

- 30 a) R¹ and R² are each independently selected from the group consisting of
 - i) a saturated or partially unsaturated C₂-C₂₄ alkyl group, and
 - ii) benzyl;

5 b) A³ is -CO-O-;
 c) n = 0-8;
 d) o = 0-8;
 e) m = 1 to 23; and
 g) R³ is -[(CH₂)_p-NR⁴]_q-R⁴.

62. The composition of claim 61 wherein, in said lipid,

10 a) R¹ and R² are each independently selected from the group consisting of
 i) a saturated or partially unsaturated C₁₈ alkyl group,
 ii) a saturated or partially unsaturated C₁₆ alkyl group, and
 iii) benzyl,
15 and m = 5.

63. The composition of claim 62 wherein, in said lipid,

20 a) A¹ and A² are both -O-;
 b) R¹ is a saturated C₁₆ or C₁₈ alkyl group and R² is a benzyl group;
 c) n = 0;
 d) o = 0;
 e) q = 0; and
 f) R⁴ is H.

25 64. The composition of claim 59 wherein, in said lipid,


30 a) A¹ and A² are both -O-;
 b) R¹ and R² are each a saturated C₁₆ or C₁₈ alkyl group;
 c) n = 0;
 d) o = 0;
 e) q = 0; and
 f) R⁴ is H.

65. A method for introducing at least one biomolecule into a cell, said method comprising the steps of

- providing a pharmaceutical formulation comprising a liposome; wherein said liposome comprises an ammonium or sulfonium ion-containing lipid, a Vitamin D derivative, a pH sensitive amphiphile, and a biomolecule in a pharmacologically acceptable carrier, and
- contacting said cell with the pharmaceutical formulation to facilitate delivery of said biomolecule within said cell.

66. The method of claim 65 wherein said biomolecule is an oligonucleotide.

67. The method of claim 65 wherein said lipid has the general structure



and optical isomers and/or salts thereof wherein:

A¹ and A² are the same or different and are -O-CO-, -O-, -S-CO- or -S-;

25 A³ is -O-, -O-CO-, -CO-O-, -S-, -S-CO-, -CO-S-, -O-CS-, -CS-O-, -CO-NH-, -NH-CO-, -CS-NH-, -NH-CS-, -NH-CO-O-, -NH-CO-NH-, -O-CO-NH-, or is absent;

R¹ and R² are the same or different and are H, or C₁ to C₂₃ saturated or partially unsaturated alkyl or aralkyl,

30 with the proviso that at least one of R¹ and R² is not H;


R³ is a C₁ to C₁₂ alkyl, aralkyl, alkaryl, heterocyclyl or heteroaryl; or

R³ is an amino acid, a dipeptide, a tripeptide, a tetrapeptide or a pentapeptide; or

R³ is -[(CH₂)_p-NR⁴]_q-R⁴,

- (CH₂)_p-NR⁴₃⁺,

5



10 wherein p is 1 to 5, q is 0 to 4, and R⁴ is H or a C₁ to C₄ alkyl and m, n and o are 0 to 8, with the provisos that m ≥ 1 and (m + n + o) ≥ 3.

15 68. The method of claim 67 wherein the molar ratio of lipid to Vitamin D derivative to amphiphile in said liposome is about 10:5:2.

69. The method of claim 68 wherein said Vitamin D derivative is Vitamin D₃.

70. The method of claim 69 wherein said amphiphile is selected from the group consisting of an aliphatic 20 carboxylic acid and DOPE.

71. The method of claim 70 wherein said carboxylic acid is oleic acid.

72. The method of claim 67 wherein, in said lipid, 25 a) A¹ and A² are each independently selected from the group consisting of: -O-, -O-CO-, and -S-;

b) R¹ and R² are each independently selected from the group consisting of

i) a saturated or partially unsaturated C₂-C₂₄ hydrocarbon group,

30 ii) benzyl, and,

iii) phenethyl;

c) A^3 is selected from the group consisting of $-O-$, $-CO-O$, $-S-$, and $-NH-CO-$, or is absent;

d) R^3 is selected from the group consisting of

5 i) saturated or partially unsaturated C_1-C_{12} alkyl or aralkyl,

ii) $-[(CH_2)_p-NR^4]_q-R^4$ wherein p is 3-4, q is from 0-4 and R^4 is H,

10 iii) $-(CH_2)_p-NR^4_3$ wherein p is 2-3 and R^3 is methyl, and;

iv) $\begin{array}{c} NH \\ || \\ -C-NR^4_2 \end{array}$ wherein R^4 is methyl.

73. The method of claim 72 wherein, in said lipid,

15 a) R^1 and R^2 are each independently selected from the group consisting of

i) a saturated or partially unsaturated C_2-C_{24} alkyl group, and

ii) benzyl;

20 b) A^3 is $-O-$;

c) $n = 0-8$;

d) $o = 0-8$;

e) $m = 1$ to 23; and

f) R^3 is $-[(CH_2)_p-NR^4]_q-R^4$.

25 74. The method of claim 73 wherein, in said lipid,

a) R^1 and R^2 are each independently selected from the group consisting of

i) a saturated or partially unsaturated C_{18} alkyl group,

30 ii) a saturated or partially unsaturated C_{16} alkyl group, and

iii) benzyl,

and $m = 6$.

75. The method of claim 74 wherein, in said lipid,

35 a) A^1 and A^2 are both $-O-$;

5 b) R¹ is a saturated C₁₆ or C₁₈ alkyl group and R² is a benzyl group;
c) n = 0;
d) o = 0;
e) q = 0; and
f) R⁴ is H.

76. The method of claim 74 wherein, in said lipid,
a) R¹ and R² are each independently selected from the
group consisting of
10 i) a saturated or partially unsaturated C₂-C₂₄
alkyl group, and
 ii) benzyl;
b) A³ is -CO-O;
c) n = 0-8;
15 d) o = 0-8;
e) m = 1 to 23; and
g) R³ is -[(CH₂)_p-NR⁴]_q-R⁴.

77. The method of claim 76 wherein, in said lipid,
a) R¹ and R² are each independently selected from the
group consisting of
20 i) a saturated or partially unsaturated C₁₆
alkyl group,
 ii) a saturated or partially unsaturated C₁₆
alkyl group, and
25 iii) benzyl,
 and m = 5.

78. The method of claim 77 wherein, in said lipid,
a) A¹ and A² are both -O-;
b) R¹ is a saturated C₁₆ or C₁₈ alkyl group and R² is
30 a benzyl group;
c) n = 0;
d) o = 0;
e) q = 0; and
f) R⁴ is H.

79. The method of claim 74 wherein, in said lipid,

- a) A^1 and A^2 are both -O-;
- b) R^1 and R^2 are each a saturated C_{16} or C_{18} alkyl group;
- 5 c) $n = 0$;
- d) $o = 0$;
- e) $q = 0$; and
- f) R^4 is H.




FIG. 1.




FIG. 2.

2/2




FIG. 3.

—●— DODMEHAP/OA/Cholesterol(Oligo)
 —■— DODMEHAP/OA/Vitamin D3 (Oligo)
 -▼- Oligo alone




FIG. 4.

—●— Corr OD (DODMEHAP)
 —■— Corr OD (DOMHYTOP)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 381/12, A61K 9/127, 47/48, C12N 15/88, C07H 21/00		A3	(11) International Publication Number: WO 96/40627	
			(43) International Publication Date: 19 December 1996 (19.12.96)	
(21) International Application Number: PCT/US96/07121		(81) Designated States: AU, CA, JP, KR.		
(22) International Filing Date: 17 May 1996 (17.05.96)				
(30) Priority Data:				
08/482,497	7 June 1995 (07.06.95)	US		
08/480,203	7 June 1995 (07.06.95)	US		
08/480,204	7 June 1995 (07.06.95)	US		
08/482,430	7 June 1995 (07.06.95)	US		
08/482,305	7 June 1995 (07.06.95)	US		
08/480,622	7 June 1995 (07.06.95)	US		
(71) Applicant: GEN-PROBE INCORPORATED [US/US]; 9880 Campus Point Drive, San Diego, CA 92121-1589 (US).				
(72) Inventors: SRIDHAR, C., Nagaraja; 1911 East Larch Street, Simi Valley, CA 93065 (US). DATTAGUPTA, Nanib- hushan; 4221 Kerwood Court, San Diego, CA 92130 (US). PATEL, Jasmin, R.; 10030-52 Scripps Vista Way, San Diego, CA 92131 (US). DAS, Aditya, Ranjan; Apartment 241, 7867 Avenida Navidad, San Diego, CA 92122 (US).				
(74) Agents: SCHNEIDER, Carol, A. et al.; Lyon & Lyon, First Interstate World Center, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).				

(54) Title: THIOCATIONIC LIPIDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF

(57) Abstract

Lipid molecules bearing a cationic charge are described. These cationic lipids are useful in the delivery of biomolecules, such as oligonucleotides, nucleic acids, peptides, diagnostic imaging agents, proteins and drug molecules. In the form of liposomes, they can effectively be used for the intracellular delivery of biomolecules for therapeutic or diagnostic purposes.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

INTERNATIONAL SEARCH REPORT

Inte onal Application No
PCT/US 96/07121

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07C381/12 A61K9/127 A61K47/48 C12N15/88 C07H21/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07C A61K C12N C07H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	J. MED. CHEM., vol. 36, no. 14, 1993, pages 2018-2025, XP000196342 S.L. MORRIS-NATSCHKE ET AL: cited in the application see page 2024, compound 26 ---	1
A	WO 91 16024 A (VICAL INC) 31 October 1991 see claims 1, 12-14, 22, 23, 28, 36-45, 53, 54 & US 5 264 618 A cited in the application ---	1, 10, 11, 20, 21 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

3

Date of the actual completion of the international search

19 December 1996

Date of mailing of the international search report

14.01.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Van Amsterdam, L

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/07121

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. Claims 1-49 and, in as far as they relate to sulfonium ion containing lipid, claims 50-79
2. Claims 50-79, in as far as they relate to ammonium containing lipid

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Appl. No.

PCT/US 96/07121

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9116024	31-10-91	US-A-	5264618	23-11-93
		AU-A-	7854791	11-11-91
		EP-A-	0523189	20-01-93
		JP-B-	2538474	25-09-96
		US-A-	5459127	17-10-95
WO-A-9010448	20-09-90	CA-A-	2049028	08-09-90
		DE-D-	69008521	01-06-94
		DE-T-	69008521	20-10-94
		EP-A-	0462145	27-12-91
		ES-T-	2055907	01-09-94
		JP-T-	4503957	16-07-92
US-A-4897355	30-01-90	US-A-	5366737	22-11-94
		US-A-	5545412	13-08-96
		US-A-	5550289	27-08-96
		US-A-	4946787	07-08-90
		US-A-	5049386	17-09-91
		US-A-	5208036	04-05-93
		AU-B-	594654	15-03-90
		AU-A-	5185386	17-07-86
		CA-A-	1288774	10-09-91
		EP-A-	0187702	16-07-86
		JP-B-	6062517	17-08-94
		JP-A-	61161246	21-07-86
		JP-B-	2546623	23-10-96
		JP-A-	7070011	14-03-95
US-A-5100662	31-03-92	AT-T-	119037	15-03-95
		AU-B-	631377	26-11-92
		CA-A-	1334165	31-01-95
		CA-A-	1337332	17-10-95
		DE-D-	68921389	06-04-95
		DE-T-	68921389	29-06-95
		EP-A-	0356339	28-02-90
		EP-A-	0626169	30-11-94
		ES-T-	2069600	16-05-95
		JP-T-	4500203	16-01-92
WO-A-9517373	29-06-95	AU-A-	1437295	10-07-95

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte: International Application No
PCT/US 96/07121

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9517373		CA-A- 2179611 EP-A- 0741689	29-06-95 13-11-96